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The worldwide dissemination of antimicrobial resistance is a growing problem causing 
increased morbidity, mortality, and financial costs. β-lactams are an important family of 
antimicrobial agents and accounts for ~46% of the total antibiotic use for systemic infections 
in Norway. Resistance to β-lactams can be caused by several factors where the production of 
enzymes, β-lactamases, is the major mechanism.  
 
Escherichia coli naturally produce small amounts of the chromosomally encoded AmpC β-
lactamase. The expression blaAmpC is noninducible and regulated by a weak promoter and an 
attenuator. Insertion sequence (IS) elements inserted into the promoter region have been 
described as one reason for the hyperexpression of blaAmpC conferring resistance to β-lactams 
such as penicillins and cephalosporins, but not 4
th
 generation cephalosporins and 
carbapenems.  
 
In this study 111 E. coli isolates with a hyperexpressed chromosomal AmpC profile were 
submitted to the Reference Center for Detection of Antimicrobial Resistance (K-res) from 
Haukeland University Hospital during 2006-2010 and a control group representing the same 
years from other Norwegian clinical microbiological laboratories (n=100) were included. The 
isolates were initially screened for an insertion of an element in the blaAmpC. A subset of 
isolates with an insertion was further molecularly characterized by sequencing of the region 
and linkage to IS911. Molecular typing was performed using multi-locus sequence typing 
(MLST) and pulsed-field gel electrophoresis (PFGE). Multi-resistance profiles were identified 
by antimicrobial susceptibility testing and further investigated by PCR and sequencing 
methods.  
 
The results from the study shows a regional clonal spread of ST131 E. coli blaAmpC-IS911 
isolates in the Bergen region of Norway. The spread of these isolates were identified both in 
isolates from Hospital 1 and 2 but also from other medical institutions such as nursing homes 
and general practitioners. In contrast, no isolates from the control group from other 
Norwegian hospitals harbored the blaAmpC-IS911 linkage. In the control group only three 
isolates from two Norwegian counties, Vestfold and Rogaland were identified with an 
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insertion in the blaAmpC region. However, in these isolates another IS-element, IS10 was 
identified. In the ST131 isolates multi-resistance was observed towards important antibiotics 
such as ciprofloxacin, gentamicin, tobramycin, and trimethoprim-sulphamethoxazole. 
Resistance to ciprofloxacin was caused by mutations in the quinolone-resistance determining 
region of the parC and gyrA genes. The resistance mechanism to the aminoglycosides 
gentamicin and tobramycin were not identified, but the isolates were negative for the 





















1. Introduction  
1.1 The era of antibiotics 
Names like Paul Ehrlich and Alexander Fleming are both important to the beginning of the 
modern “antibiotic era”. Paul Ehrlich hoped to cure syphilis by finding a drug targeted 
directly at the source of disease, the spirochete Treponema palladium. He executed a large-
scale screening resulting in the discovery of an effective drug, named Salvarsan, in 1909. This 
was for many years to come the most frequently prescribed drug, until replaced by penicillin 
in the 1940s. The screening process used by Ehrlich inspired others and resulted in the 
discovery of, among other, sulfa drugs, namely sulfonamidochrysoidine (Prontosil). This was 
a non-patented drug easy to mass produce which early led us to the problem of sulfa drug 
resistance. Still, probably the most known antibiotic, penicillin, was in 1928 discovered by 
Alexander Fleming. His observations on the antimicrobial effects of the fungus Penicillum 
chrysogenum against Staphylococci strains revolutionized the treatment of infectious diseases. 
Howard Florey and Ernst Chain, both part of an Oxford team, were first in 1940 able to purify 
penicillin for clinical testing [1].  
 
The discovery of Salvarsan, Prontosil and penicillin were followed by decades of new 
antimicrobial agents identified and introduced into clinical use, as illustrated in the timeline 
(figure 1). The period from the 1950s throughout the 1970s are reckoned as the golden era of 












In early years the term “antibiotics” was most commonly used. This referred to natural 
metabolic products aimed to inhibit or kill microorganisms produced by fungi, actinomycetes, 
and other types of bacteria. The production of antibiotics was beneficial to the organisms as a 
competitional factor when claiming habitat and nutrients. The antibacterial agents used today 
are derivatives of natural products chemically modified (i.e. semi-synthetic) to enhance their 
properties. Therefore the term “antimicrobial” agent is a more descriptive term. Some of the 





Antibacterial agents can be classified in three ways: 
1. According to whether they are bactericidal or bacteriostatic. 
2. By target site. 
3. By chemical structure.  
 
The most used classification is by target site as classification by chemical structure alone is 
not practical due to the diversity of antimicrobial agents. The ability of an antimicrobial agent 
to inhibit or kill a microorganism also varies depending on the organism. For example 
chloramphenicol can inhibit the growth (bacteriostatic) of Escherichia coli while it kills 
(bacteriocidal) Haemophilus influenzae. The five main target sites of antimicrobial agents are; 
(i) cell wall synthesis, (ii) protein synthesis, (iii) nucleic acid synthesis, (iv) metabolic 
pathways, and (v) cell membrane functions, all illustrated below in figure 2 [2].  
 
 







1.2 β-lactam antimicrobial agents  
β-lactam antimicrobial agents are a large family of bactericidal agents. The family consists of 
penicillins, cephalosporins, cephamycins, carbapenems, and monobactams (table 1). The 
structure of the β-lactams varies around the β-lactam ring, a consistent structure of the class. 
Penicillins, for example, have a five-membered ring attached to the β-lactam ring, while 
cephalosporins have a six-membered ring in addition to differing side chains attached to the 
rings [2]. β-lactams have for years been the most important and the most used antibiotic. In 
Norway β-lactams represent ~46% of the total antibiotic use for systemic infections [3]. The 
last developed group of β-lactams, the carbapenems is used as a last resort against bacterial 
infections. They are preferred when treating serious infections caused by pathogens with a 
multi-drug resistance profile [4].  
 
Table 1. Classification and antimicrobial spectrum of β-lactams [5] 
  Antimicrobial spectrum 
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1.2.1 Mechanism of action 
Carboxypeptidases, transglycosylases and transpetidases are all membrane proteins in the 
bacterial cell wall. These enzymes are important in the final stages of synthesizing new cell 
wall. More precisely, the enzymes function in the cross-linking of two glycan-linked peptide 
chains. Without this cross-linking the cell wall loses its stability and strength and will 
therefore result in cell lysis. β-lactams have the ability to bind to these membrane enzymes, 
hence the name “penicillin binding proteins” or PBPs. When penicillin binds to the PBPs they 
inhibit the cross-linking reaction leading to an accumulation of precursor cell wall units and to 
an activation of the autolytic system, resulting in cell lysis. Several PBPs are known and both 
intra- and interspecies variations are found, which explains the varying antimicrobial 
spectrum of β-lactams [2, 5, 6].  
 
1.3 Antimicrobial resistance  
The increase of bacterial resistance to antimicrobial agents in our society is a problem caused 
by many factors. From the bacterial point of view, resistance in many cases means survival 
and is highly valued. Bacterial strains have evolved numerous strategies to avoid 
antimicrobial agents like producing enzymes that inactivate or modify antimicrobial agents, 
have an altered binding site for the antimicrobial agent, or restrict access to the target by 
reduced permeability or efflux mechanisms [2].  
 
Clinical bacterial resistance is classified according to the “SIR” classification using the 
following categories; susceptible (S), intermediate (I), or resistant (R).  
 
Susceptible: A bacterial strain is said to be susceptible to a given antibiotic when it is 
inhibited in vitro by a concentration of the drug that is associated with a high likelihood of 
therapeutic success [7]. 
 
Intermediate: The sensitivity of a bacterial strain to a given antibiotic is said to be 
intermediate when it is inhibited in vitro by a concentration of this drug that is associated with 
an uncertain therapeutic effect [7]. 
15 
 
Resistant: A bacterial strain is said to be resistant to a given antibiotic when it is inhibited in 
vitro by a concentration of this drug that is associated with a high likelihood of therapeutic 
failure [7]. 
 
A noteworthy dilemma is that our extensive use of antibiotics results in us selecting for 
resistant bacteria. We need to implement ways to quickly identify and effectively prevent the 
further spread of resistant strains. Factors like the increased air travel also add to the spread of 
resistance. We are able to travel around the world in much less than 80 days, bringing 
bacterial souvenirs back with us. Another important fact and a highly increasing phenomenon 
is the term “Medical Tourism”. Due to long waiting lists and high priced insurances people 
choose to travel abroad for cheaper surgeries. India is one of the most visited countries 
offering a wide range of medical procedures like dental work and corrective surgery [8]. The 
problem is that India is also a country highly associated with antimicrobial resistance, 
exemplified by the recent spread of the carbapenemase NDM-1 [9].  
 
Still, the most dramatic consequences of resistance are the increased morbidity and mortality. 
In addition to this, resistance causes an added cost to the society in the form of extended 
hospital stays, blocking of hospital beds for new patients, and repeated visits from the 
physician resulting in a lowering of the productive time. In the European region for 2007 it 
was estimated as many as 5503 excess deaths caused by blood stream infections (BSIs) due to 
methicillin resistant Staphylococcus aureus (MRSA) and 2712 deaths by BSIs caused by third 
generation cephalosporin-resistant E. coli. Numbers as high as 255,683 (BSIs by MRSA) and 
120,065 (BSIs by third generation cephalosporin-resistant E. coli) were registered for excess 
hospital bed-days. For 2007 the costs of excess hospital stay due to BSIs caused by MRSA or 
third generation cephalosporin-resistant E. coli were estimated to 62 million Euros [10].  
 
In general resistance in Gram-negative bacteria is faster growing compared to Gram-positives. 
This confers a global problem as there are fewer new and developmental antibiotics targeted 




1.3.1 Mechanisms of resistance 
Resistance mechanisms can either be an intrinsic property of a bacterial specie or an acquired 
trait. Acquired resistance occurs as a result of chromosomal mutations (point mutations, 
deletions, inversions, insertions, etc.) or by the acquisition of genetic elements. Some species 
of bacteria are naturally resistant towards some types of antimicrobial agents. Intrinsic 
resistance covers a whole bacterial specie and provides resistance without the addition of 
genetic elements or mutations. Bacteria that lack a cell wall, e.g. mycoplasma, will as a 
consequence be intrinsic resistant to β-lactams [11].  
 
1.3.2 Mutations  
During DNA replication a randomly occurrence of incorrect nucleotides are incorporated. 
Mutations can lead to alterations in the drug target, drug-inactivation, the up- or down-
regulation of efflux systems, as well as the loss or activation of porins and active transporters 
affecting the uptake pathway. In general a mutation will cause resistance to one class of 
antimicrobial agents, but changes affecting impermeability and efflux may result in a multiple 
resistance towards several classes of antimicrobial agents [12].  
 
1.3.3 Horizontal gene transfer 
Resistance genes are able to spread from one bacterium to another by the means of processes 
like conjugation, transformation, and transduction. The exchange of genetic material can 
occur between strains of the same specie and between species or genera [6].  
 
Conjugation is the transfer of genes from one bacterium to another, requiring cell-to-cell 
contact. The process involves a donor that contain a transferrable element and a recipient that 
does not. The donor produces a pilus that attaches the two cells. The outer membrane of the 
two cells fuse and DNA can be transferred from the donor to the recipient. Both plasmids and 
chromosomal parts can be moved. The recipient is referred to as a transconjugant and can act 




Transformation is the uptake of naked DNA from the environment. Cell lysis will release 
fragmented DNA that naturally competent bacteria can take up. Typically only short DNA 
fragments are exchanged [6].  
 
Transduction involves the transfer of host genes from one bacterium to another by bacterial 
viruses. In generalized transduction, virus particles randomly incorporate fragments of the 
bacterial cells chromosomal DNA, but the efficiency is low. In specialized transduction, the 
DNA of a temperate virus excises incorrectly and takes adjacent host genes along with it, also 
leaving some phage genes behind. The transducing efficiency here may be very high [6].  
 
1.4 Resistance elements 
 
Plasmids are genetic elements that replicate independently of the host chromosome. They do 
not have an extracellular form and exist inside cells as free, often circular, double stranded 
DNA. Plasmids consist of plasmid backbones necessary for their own propagation and 
survival (e.g. replication, maintenance, and morbidity) as well as accessory DNA. Examples 
of plasmid-encoded genes are resistance genes and virulence factors. Plasmids range in size 
from a few thousands to hundreds of thousands of base pairs (bp) and can exist in multiple 
copies within a bacterium. Not all plasmids can coexist in the same cell, they are incompatible 
as they then often share the same replication- and partitioning systems. Based on this a 
classification scheme was deduced where all plasmids belong to an Inc group (incompatibility 
group). Plasmids belonging to the same group cannot coexist stably in a cell, while plasmids 
of different groups have this ability. As most plasmids are small, have a relatively high copy 
number, carry easily selectable traits, and have one or few sites for restriction enzymes they 
are highly suitable as cloning vectors [2, 13].  
 
Transposons are elements of DNA able to move from one place to another within the 
genome. These elements are known to be found in all organisms, including humans. The 
movement of DNA is promoted by enzymes called transposases. The transposons vary in 
length from about 1000 bp, only carrying the genes for the transposases, to larger elements 
also harboring other genes, including resistance encoding genes. Common for transposons are 
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the inverted terminal repeats and short direct repeats for the target DNA. Transposons 
generally have low specificity for the target enabling it to be inserted at several places in the 
DNA [13].  
 
Insertion sequence (IS) elements are the smallest type of transposons found in bacterial 
cells. They range in size from about 750 to 2000 bp and generally do not encode much more 
than the transposases required for transposition [13]. As IS elements do not encode resistance 
genes their mere insertion into the genome of bacteria cause alterations that may result in 
resistance to antimicrobial agents. Canadian hospitals studying E. coli isolates resistant to 
cefoxitin found IS10 and IS911 incorporated into the promoter region of the blaAmpC gene, 
leading to an overproduction of the enzyme [14].  
 
IS911 belongs to the largest family of IS elements, the IS3 family. It is composed of a 
transposase, OrfAB, a regulatory protein, OrfA, and right and left inverted repeats (IRR and 
IRL) at the ends. The element is 1250 bp in size and its transposition occurs in several steps, 
involving two promoters (PIRL and Pjunc). OrfA regulates the transposition and also facilitates 
the random insertion of IS911 into the genome of bacterial cells [15, 16].  
 
1.5 β-lactam resistance mechanisms  
Resistance to β-lactams is generally the result of one or more of the three following 
mechanisms [2, 4]: 
 
1. Resistance by alteration in target site. 
2. Resistance by alteration in access to the target site. 
3. Resistance by production of β-lactamases. 
 
Some bacteria produce alternative PBPs that have a lower affinity for β-lactams than the 
normal PBPs. The cell wall synthesis is not interrupted as these PBPs are able to continue the 
work while the normal PBPs are inhibited. This resistance mechanism is found in methicillin-
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resistant staphylococci (Staphylococcus aureus (MRSA) and Staphylococcus epidermidis 
(MRSE)) where the mecA gene encodes the additional PBPs [2].  
 
Gram-negative bacteria are naturally less susceptible to β-lactams compared to Gram-positive 
bacteria due to a more difficult-to-reach target. For the β-lactams to reach the PBPs they need 
to be able to diffuse through protein channels in the outer membrane. Mutations in these porin 
channels result in resistant bacteria as the access to the target site is blocked. If other types of 
antimicrobial agents use the same porins cross resistance may be seen [2].  
 
Efflux pumps are transport proteins involved in the extrusion of toxic substrates found in both 
Gram-negative and Gram-positive bacteria. These pumps also play a part in β-lactam 
resistance as the antimicrobial agents are actively pumped out of the bacterial cell. Some 
efflux pumps are drug specific while others may act on multiple antimicrobial agents 
increasing the risk of multidrug resistant bacteria. High-level resistance due to efflux alone is 
not of great concern, but it makes the bacteria better equipped to survive in the presence of 
antimicrobial agents and possibly develop further mutations in genes encoding the target site 
of antibiotics [17].  
 
1.5.1 β-lactamases  
An enzyme able to hydrolyze penicillin was identified in E. coli as early as in 1940, before 
penicillin was taken into clinical use, proving a natural origin [4]. The β-lactamases execute 
their effect in hindering the work of β-lactams by hydrolyzing the β-lactam ring structure. The 
enzymes can be encoded on both plasmids and chromosomes and are highly selected for by 
the extensive use of β-lactams in our society. The β-lactamases are located differently in 
Gram-positive and Gram-negative bacteria. The enzymes are mostly extracellular in Gram-
positive bacteria, while periplasmic in Gram-negative species. There has been indentified over 





Classification of β-lactamases can be done according to the functional properties (Bush-
Jacoby-Medeiros scheme) or by the molecular class (Ambler classification scheme). The 
molecular classification is based on the sequence similarities and catalytic mechanisms. Class 
A, C, and D all have a serine at their active site, while class B has a zinc based active site 
(table 2). The functional classification groups are based on the substrate profile of the enzyme 
and its inhibitory profile. Group 1 is cephalosporinases, group 2 consist of broad-spectrum, 
inhibitor-resistant, and extended-spectrum beta-lactamases and serine carbapenemases. The 
last group,  group 3, holds the metallo-β-lactamases (table 3) [18, 19]. 
 
Table 2. Ambler classification schemes for bacterial β-lactamases[19].  
Ambler classification scheme 
Class  
A Serine Based Penicillinases 
B Zinc Based Metallo-β-lactamases 
C Serine Based Cephalosporinases 















Table 3. Bush-Jacoby-Medeiros classification scheme for bacterial β-lactamases [18]. 
Bush-Jacoby-Medeiros Inhibited by 
Group Substrate(s) Characteristic(s) CA or 
TZB 
EDTA 
1 Cephalosporins Greater hydrolysis of cephalosporins than 
benzylpenicillin; hydrolyzes cephamycins 
 
No No 








2b Penicillins, early 
cephalosporins 








Increased hydrolysis of oxyimino-β-lactams 












Increased hydrolysis of oxyimino-β-lactams 
combined with resistance to clavulanic acid, 
sulbactam, and tazobactam 
No No 















Hydrolyses cloaxcillin or oxacillin and 
oxyimino-β-lactams 
Variable  No 







Hydrolyzes cephalosporins. Inhibited by 
clavulanic acid but not aztreonam 
Yes No 




3a Carbapenems Broad-spectrum hydrolysis including 
carbapenems but not monobactams 
 
No Yes 
3b Carbapenems Preferential hydrolysis of carbapenems No Yes 
* CA: clavulanic acid, TZB: tazobactam 
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1.5.2 AmpC β-lactamases 
The early discovery of a bacterial enzyme able to destroy penicillin was an important 
discovery for the future. Later on the enzyme was named AmpC β-lactamase and it was first 
seen in E. coli. As penicillin resistance was a spreading problem scientists started to look 
closer into the genetics of the resistance mechanisms. The structural gene for the production 
of the β-lactamase was named blaAmpC and the sequence of the gene from E. coli was reported 
in 1981. The AmpC enzymes are classified as class C according to the Ambler structural 
classification and group 1 based on the functional classification scheme of Bush et al. [18, 
20]. 
 
The molecular masses of typical AmpC enzymes range from 34 to 40 kDa. They have 
isoelectric points of ˃ 8.0 and are generally located in the bacterial periplasm. Although 
AmpC enzymes are active against penicillins, their activity is even greater towards 
cephalosporins, with the exception of 4
th
 generation cephalosporins (cefepime and cefpirome). 
They also hydrolyze cephamycins, like cefoxitin and cefotetan, and monobactams like 
aztreonam. AmpC enzymes are poorly inhibited by clavulanic acid, sulbactam, and 
tazobactam, and not at all by EDTA. While cloaxillin, oxacillin, and boronic acid are 
considered good inhibitors [20].  
 
The structures of the enzymes are similar to the β-lactamases of class A. The distinguishing 
factor is the more open binding site of the class C enzymes, enabling them to better 
accommodate the side chains of the cephalosporins. The molecular structure of the enzymes 
consists of an α-helical domain on one side and an α/β domain on the opposite site. The active 
site is located in the center of the enzyme, divided into an R1- and R2- site, each targeted at a 
side chain of the antimicrobial agent [20].  
 
In many genera of Enterobacteriaceae, including Citrobacter, Serratia, and Enterobacter, the 
expression of AmpC is normally low, but inducible by exposure to β-lactams. Both Shigella 
and E. coli are exceptions that by lacking the gene ampR are noninducible but rather regulated 
by promoter and attenuator mechanisms [20]. Still, high-level producers of E. coli have been 
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found in clinical specimens where resistance to cephalosporins is achieved by mutation or 
insertion elements creating a stronger promoter [21, 22].  
 
Studies of the AmpC promoter region in E. coli K-12 have shown that the gene is preceded by 
an frd operon (figure 3). This operon consists of four genes of varying size; frdA, frdB, frdC, 
and frdD, encoding a fumarate reductase enzyme (by the two largest subunits), and an enzyme 
anchor to the cytoplasmic membrane (by the two smallest subunits). There is an overlapping 
region of the frdD and the AmpC where the promoter of AmpC is part of the preceding gene 
[23]. The AmpC attenuator mediates the growth rate control of the AmpC gene product as 
well as being a transcriptional terminator for the frdD operon. As the two operons are tightly 
connected mutations in the overlapping region will affect both regions [24-26].  
 
 
Figure 3. Overview of the E. coli chromosomal AmpC and frd regions. Figure modified from 
Bergstrøm et al. [26].  
 
Plasmid-mediated AmpC genes have been isolated from both nosocomial and non-nosocomial 
isolates from all over the globe. They have been identified since 1989 being more easily 
detected in species not expected to produce an AmpC β-lactamase. Several families of 
enzymes are known like CMY, FOX, ACC, LAT, MIR, ACT, and MOX, with only minor 
amino acid variations separating them. The plasmid-encoded β-lactamases are related to the 
chromosomally-encoded enzymes. CMY-2, the most common plasmid-mediated AmpC β-
lactamase from a global perspective, shows a relatedness of 96% to chromosomal AmpC β-
lactamases from Citrobacter freundii. Other resistance genes conferring resistance to 
aminoglycosides, chloramphenicol, quinolones, sulfonamide, tetracycline, and trimethoprim 
are often accompanying the AmpC β-lactamases on the plasmids. Other β-lactamase encoding 
genes can also be found including blaTEM-1, blaPSE-1, blaCTX-M-3, blaSHV variants, and blaVIM-1. 
In order to mobilize a gene from the chromosome onto a plasmid, transposable elements are 
needed. The insertion sequence ISEcp1 is associated with several variants of CMY and ACC 
and holds the ability to mobilize chromosomal β-lactamases onto plasmids as well as provide 
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a highly efficient promoter for neighboring genes. Also the ISCR1, an insertion sequence 
common region, is known to be involved in the transfer of other AmpC β-lactamase genes 
into complex class 1 integrons [20]. 
 
1.6 Multi-resistance mechanisms; aminoglycosides and fluoroquinolones  
1.6.1 Aminoglycoside resistance by the AAC(6`)-Ib-cr enzyme 
Gentamicin, amikacin, and tobramycin are all aminoglycosides, antimicrobial agents targeted 
to inhibit the protein synthesis of bacteria. The most important mechanism of acquired 
resistance to aminoglycosides is the production of enzymes capable of modifying and 
inactivating the antimicrobial agents. The resistance genes are often carried on plasmids and 
they are transferrable between different bacterial species [2]. Recently a variant of a common 
aminoglycoside N-acetyltransferase, AAC(6`)-Ib, was discovered to also provide resistance to 
the fluoroquinolones ciprofloxacin and norfloxacin. Two amino acid mutations enable the 
naturally evolved enzyme to confer resistance to synthetic antimicrobial agents. By itself the 
degree of resistance by AAC(6`)-Ib-cr is low, but when accompanied by other quinolone 
resistance genes the level is raised close to the clinical breakpoint for susceptibility [27].  
 
1.6.2 Fluoroquinolone resistance by mutations in the genes parC and gyrA 
Resistance to fluoroquinolones in strains of E. coli was found to be caused by mutations in the 
genes encoding subunits of DNA gyrase and topoisomerase IV (gyrA and parC, respectively), 
the targets of quinolones. The described mutations for GyrA are generally found between 
position 67 and 106, a region referred to as the quinolone-resistance determining region 
(QRDR). Mutations in parC mostly occur at codons 80 and 84 (table 4). A single gyrA 
mutation may lead to resistance to nalidixic acid, but additional mutations in gyrA and/or in 







Table 4. Mutations described in GyrA and ParC of quinolone-resistant strains of E. coli [28] 
 Codon Wild type amino acid Mutations described 
GyrA 51
a








 83 Ser Leu, Trp, Ala, Val 
 84 Ala Pro, Val 
 87 Asp Asn, Gly, Val, Tyr, His 
 106
a 
Gln Arg, His 
ParC 78 Gly Asp 
 80 Ser Ile, Arg 
 84 Glu Lys, Val, Gly 
a
 Only described in mutants obtained in vitro.  
*Ala: Alanine, Arg: Arginine, Asn: Asparagine, Asp: Aspartic acid, Cys: Cysteine, Gln: 
Glutamine, Gly: Glycine, Glu: Glutamic acid, His: Histidine, Ile: Isoleucine, Leu: Leucine, 
Lys: Lysine, Pro: Proline, Ser: Serine, Trp: Tryptophan, Val: Valine, Tyr: Tyrosine.  
 
1.7 Enterobacteriaceae  
The Enterobacteriaceae consists of several genera and species, where some of the more 
common ones from a clinical perspective are E. coli, Klebsiella pneumonia, Shigella, 
Salmonella and Enterobacter. Members of the family can be found in a wide range of habitats 
like on plants and in soil, water, and the intestines of humans and animals. Properties shared 
by the Enterobacteriaceae family include that they are Gram-negative rods, do not form 
spores, are motile with peritrichous flagella or are non motile, grow both aerobically and 
anaerobically, ferment D-glucose and other sugars, often with gas production, are catalase 
positive and oxidase negative [29].  
 
1.7.1 Escherichia  
The genus consists of six species; Escherichia albertii, Escherichia blattae, E. coli, 
Escherichia fergusonii, Escherichia hermannii, and Escherichia vulneris. Apart from E. 
blattae, a commensal organism of cockroaches, all species have been isolated from human 




1.7.2 Escherichia coli 
E. coli is the species of Escherichia usually isolated from human specimens. It is a motile 
bacterium, facultative anaerobe with or without a capsule. E. coli is associated with urinary 
tract infections, diarrheal diseases, bacteremia, and meningitis, caused primarily by a limited 
number of pathogenic clones. The normal habitat of E. coli is the gut of humans and animals 
and the common route of infection is by contact and ingestion (oral-fecal). It possesses several 
antigens that are used for serotyping; O (somatic), H (flagellar), K (capsular), and F (fimbral) 
[2, 29].  
 
During recent years the E. coli clone O25:H4-ST131 associated with urinary tract and blood 
stream infections has been observed worldwide. The clone has been isolates from both 
hospital settings and long-term care facilities as well as from the community. E. coli ST131 
clones are known to be diverse and may harbor a variety of β-lactamase genes like blaTEM, 
blaOXA, and blaCTX-M, but are especially linked to the worldwide dissemination of CTX-M-15, 
an extended spectrum β-lactamase (ESBL). The clones usually belong to phylogenetic group 














2. Aims and hypothesis for the study 
In a previous Norwegian study by Igeltjørn five E. coli isolates showing an increased 
resistance to cephalosporins were found to hold IS911 in the AmpC region. Four of the 
isolates were clonally related by PFGE, of sequence type 131, and from the Bergen region. 
The last isolate was isolated from Vestfold hospital, sequence type 550, and not related to the 
others by PFGE [33]. This study aims to continue the work and discoveries started by 
Igeltjørn and continued by the Reference Center for Detection of Antimicrobial Resistance 
(K-res).  
 
The aims for this study was (i) To investigate a putative increase in β-lactam-resistant clinical 
E. coli isolates submitted to K-res from the Department of Microbiology at Haukeland 
University Hospital with a phenotype and genotype indicating hyperexpression of the 
chromosomal blaAmpC gene, (ii) Molecular characterization of  the isolates and compare with 
isolates from other Norwegian microbiology laboratories to reveal the mechanism of 
resistance and if there is dissemination of a successful clone in the Bergen region. 
 
Hypothesis:  
1. There is a clonal outbreak of β-lactam-resistant E. coli isolates in the western part of 
Norway (Bergen region). 
2. The dissemination of E. coli isolates in the Bergen region is caused by a successful 







3. Materials and methods  
3.1 Strain collections 
Three strain collections for this study was selected by an extensive data mining search 
through the paper copies of the requisitions and reports from K-res during the period 2006-
2010. The data was typed into a Microsoft Excel database. 
 
Collection 1: E. coli isolates (n=111) from Department of Microbiology at Haukeland 
University Hospital, representing all E.coli isolates received at K-res from 2006 until 2010 
and assigned as “Chromosomal AmpC with or without impermeability”. In order to be 
assigned this profile an isolate has to have a phenotypic resistance profile consistent with 
AmpC production and negative plasmid-mediated AmpC PCR.  
 
Collection 2: E. coli isolates (n=100) selected from isolates received at K-res from 2006 until 
2010 characterized as “Chromosomal AmpC with or without impermeability” representing a 
range of other diagnostic microbiological laboratories in Norway. The isolates were used as a 
control group for this study. In the process of selecting isolates, emphasis was given to that, if 
possible, all parts of the country should be included and that the isolates used should have a 
time range throughout the given year.  
 
Collection 3: A selection of 12 PCR positive for an insertion in the blaAmpC region E. coli 
isolates from both Haukeland (n=9) and other laboratories (Vestfold n=2 and Haugesund n=1) 
were chosen for an extended characterization. The following studies were made for these 
isolates: multi-locus sequence typing (MLST), sequencing of the blaAmpC region, extended 
antimicrobial susceptibility testing (ciprofloxacin, mecillinam, nitrofurantoin, fosfomycin, 
tobramycin, gentamicin, amikacin, and trimethoprim- sulfamethoxazole) and PCR/sequencing 




3.2 Phenotypic methods 
3.2.1 Etest susceptibility testing 
The antimicrobial susceptibility of a microorganism can be determined by using a gradient 
test such as Etest. This is a quantitative method developed to establish the minimum 
inhibitory concentration (MIC) of an agent, the lowest concentration that inhibits visible 
microbial growth (i.e. colonies on an agar plate or turbidity in broth culture). An Etest is a 
plastic strip with a predefined and immobilized gradient of an antimicrobial agent. When the 
strip is placed onto an inoculated agar plate, the antimicrobial agent diffuses into the agar. 
After an overnight incubation the MIC can be read on the strip at the point where the edge of 
the microbial growth meets the Etest strip [6]. The results were interpreted according to the 
clinical breakpoints set by the European Committee on Antimicrobial Susceptibility Testing 
(EUCAST) (table 5).  
 
In this study the following Etests were used: 
1. For collection 3 (n=12): ciprofloxacin, mecillinam, nitrofurantoin, fosfomycin, 
tobramycin, gentamicin, amikacin, and trimethoprim- sulfamethoxazole.  
2. Complementing Etests for the E. coli isolates positive for an insertion in the blaAmpC 
region where they were lacking: ceftazidime, cefuroxime, aztreonam, and the 










Table 5. MIC interpretive standards (mg/ml) determined by the European Committee on 
Antimicrobial Susceptibility Testing (EUCAST v.2.0, 01.01.2012, 
http://www.eucast.org/clinical_breakpoints/ and NordicAST v.2.0, 01.01.2012) 
Antimicrobial agent S≤ R> 
Ciprofloxacin 0.5 1 
Mecillinam 8 8 
Nitrofurantoin 64 64 
Fosfomycin 32 32 
Tobramycin 2 4 
Gentamicin 2 4 
Amikacin 8 16 
Trimethoprim- Sulfamethoxazole 2 4 
Ceftazidime 1 4 
Cefuroxime 8 8 
Aztreonam 1 4 
Ampicillin 8 8 
Amoxicillin-Clavulanate 8 8 
Piperacillin-Tazobactam 8 16 
Cefoxitin  8 8 
Cefotaxime 1 2 
Meropenem 2 8 
S: susceptible, R: resistant 
 
3.3 Molecular methods 
3.3.1 DNA isolation from bacteria 
Bacterial DNA needed for this study was isolated using the QIAGEN GenoM-48 BioRobot 
(QIAGEN, Hilden, Germany) according to the manufacturer’s protocol. The robot executes 
all the steps of the isolation and all the reagents used are supplied by MagAttract DNA M48 
Mini Kit (QIAGEN). The bacterial cells are lysed and the DNA binds to magnetic particles. 
The DNA is then washed several times before eventually eluted in water [34].  
Procedure: 
1. Lactose agar plates with ampicillin were streaked and incubated over night at 37°C. 
2. 0.5 McFarland suspensions were made in 0.85% NaCl and 200µl was transferred to 
sample tubes. 
3. The sample tubes were placed in the robot and the program was started. 
4. After isolation, the DNA was stored at 2-8°C. 
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3.3.2 Polymerase Chain Reaction (PCR)  
Polymerase chain reaction (PCR) is a method comparable to a copy machine, where specific 
regions of DNA are amplified in vitro. A heat stable DNA polymerase is necessary along with 
a pair of oligonucleotide primers for the DNA region to be amplified, as well as a supply of 
deoxynucleotide triphosphates (dNTPs). The method is rapid and simple in execution and is 
commonly used in a wide range of endeavors, from paleontology to criminology [35]. 
 
In general the PCR reaction follows three steps [35]: 
1. Denaturation: The reaction is heated to a temperature, approximately 95ºC, where the 
hydrogen bonds of the double helix are broken creating single strands of template 
DNA.  
2. Annealing: The temperature of the reaction is lowered to about 50-60ºC, enabling the 
primers to attach to the complementary regions on the single-stranded template DNA. 
This creates short segments of double-stranded DNA where the DNA polymerase is 
able to attach.  
3. Extension/elongation: The temperature is raised to 72ºC, the optimal temperature for 
the Taq polymerase used in this study, and the nucleotides are added to the 3´end of 
the primers by the polymerase. New DNA strands complementary to the DNA 
template are synthesized.  
 
This process is repeated for 20-30 cycles which yields an amplification of from a millionfold 




). As each step in the process is 
rather quick, the amplification can be done in a few hours. The amplification of the template 







For this study hot-start PCRs were performed using JumpStart REDTaq ReadyMix PCR 
Reaction Mix (Sigma Aldrich, St. Louis, USA). This type of PCR has a higher specificity by 
lowering the non-specific primer annealing. The DNA polymerase provided in the reaction 
mix before mentioned, is inactivated by antibodies until the reaction reaches a given 




1. For each reaction 2.5µl template DNA was added to 22.5µl PCR mastermix 
(Appendix B, table 1). 
2. Positive and negative controls were included, as well as a mastermix control 
containing ddH2O (Appendix B, table 5).  
3. The PCR was run on a PCR thermocycler (Applied Biosystems, Foster City, Ca, USA) 
according to the appropriate program depending on the annealing temperature of the 
primers (Appendix B, table 3).  
 
3.3.3 Agarose gel electrophoresis 
Gel electrophoresis is a method used to separate, identify and purify DNA and RNA 
fragments through an electrical field. The gel acts as a sieve where small molecules migrate 
faster through than larger molecules. The rate of movement for a molecule is determined by 
their charge-to-mass ratio. Gel electrophoresis can therefore be used in determining the 
unknown size of DNA or RNA by comparing to a molecular ladder with molecules of known 
sizes. As nucleic acid molecules are naturally negatively charged they will migrate towards 
the positively charged electrode of the electrical field [36].  
 
The location of the DNA in the gel is determined by using low concentrations of fluorescent 
intercalating dyes, like ethidium bromide or GelRed, to be visualized under UV light. It is 
possible to retrieve the bands of DNA from the gel, which can be used for a variety of other 





1.  1% agarose (Seakem LE agarose, Lonza, Rochland, ME, USA) was dissolved in 
0.75X TBE (Appendix B, table 7) by boiling the solution in a microwave oven.  
2. 0.5µg/ml EtBr (Sigma-Aldrich) or GelRed (Biotium) was added for staining of the 
DNA molecules. 
3. The solution was poured into a gel tray of the electrophoresis apparatus containing the 
combs. The gel was left to solidify for about 30 minutes.  
4. After removing the combs, 5µl of each PCR product was loaded into the gel wells.  
5. 5µl of 1 Kb Plus DNA molecular marker (Invitrogen, Carlsbad, CA, USA) was loaded 
into the flanking wells (Appendix B, figure 1). 
6. The electrophoresis was run at 120 V for about 90 minutes.  
7. The DNA bands were visualized using GelDoc System (BioRad).  
 
3.3.4 PCR-based detection of 16S rDNA 
As a control of a successful DNA isolation universal primers were used to amplify a region of 
about 1500bp of the 16S rDNA followed by agarose gel electrophoresis. This shows the 
quality of the DNA extraction and is beneficial to check before starting further studies with 
the DNA. Clear 16S rDNA bands on a gel indicate a strong product and a high quality of the 
DNA template. If the amplification is poor or unsuccessful this indicates failed DNA 
isolation, DNA degradation or the presence of PCR inhibitors [38].  
 
Mastermix, primers, and PCR conditions for detection of 16S rDNA are described in 
Appendix B, table 1, 3-4.  
 
3.3.5 PCR-based screening for an insertion into the blaAmpC region  
All the isolates of the strain collections were screened for possible insertion into the blaAmpC 
region using one primer located in the actual blaAmpC gene and one primer located in frdD in 
front of the AmpC promoter region. The screening was performed using PCR and agarose gel 
electrophoresis, as previously described. Mastermix, primers, and PCR conditions are 
described in Appendix B, table 1, 3-4.  
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3.3.6 PCR-based linkage of IS911 with blaAmpC  
The AmpC with insert-positive isolates intended for PFGE study (n=28) were investigated for 
the linkage between blaAmpC and the IS-element IS911 (table 3, Appendix A), only excluding 
the following isolates; K34-08, K36-03, K61-40, K67-10. The IS911 specific primer IS911-
1F and the blaAmpC-binding primer IS911-4R were used (table 4, Appendix B).  
 
The screening was performed using PCR and agarose gel electrophoresis as previously 
described. Mastermix, primers (IS911-1F and IS911-4R), and PCR conditions are described 
in Appendix B, table 1, 3-4.  
 
3.3.7 PCR-based screening for blaTEM 
Strain collection 3 was screened for the precence of β-lactamase TEM. TEM-1 was the first 
plasmid mediated β-lactamase described in Gram-negative bacteria and is still commonly 
found. It is responsible for up to 90% of ampicillin resistance in E. coli. A large number of 
TEM variants have been described (>130) where single amino acid substitutions occur at a 
limited number of positions [39]. To confirm the variant of TEM present sequencing of the 
region is necessary.  
 
The screening was performed according to the previously described procedure for PCR and 
gel electrophoresis. Mastermix, primers, and PCR conditions are described in Appendix B, 
table 1, 3-4.  
 
3.3.8 PCR-based screening for aac(6´)-Ib-cr 
Strain collection 3 was screened for the presence of the gene encoding the aminoglycoside 
modifying enzyme AAC(6´)-Ib-cr. This variant of AAC(6´)- Ib encodes an aminoglycoside 
acetyltransferase that confers reduced susceptibility to ciprofloxacin. The cr variant has amino 




The screening was performed using the PCR- and gel electrophoresis protocols previously 
described. Mastermix, primers, and PCR conditions are described in Appendix B, table 1, 3-4 
 
3.3.9 Sequencing of the Quinolone resistance determining regions  
Quinolones, including fluoroquinolones, consist of a large family of bactericidal synthetic 
agents that interfere with the replication of the bacterial chromosome. Mutations in the target 
area where the quinolones attach confers resistance [2]. These mutations are often seen within 
conserved regions of two genes, gyrA and parC. The genes encode, respectively, the A 
subunit of DNA gyrase and the homologous A subunit of topoisomerase IV. The conserved 
regions within the genes were named “Quinolone Resistance Determining Regions”, 
shortened to QRDR [27].  
 
Collection 3 was screened for parC and gyrA. The screening was performed using two sets of 
primers (Appendix B, table 4) according to the general protocol for PCR and gel 
electrophoresis described earlier. Mastermix and PCR conditions are described in Appendix 
B, table 1 and 3. The PCR products were purified and sequenced as described below.  
 
3.3.10. PCR-based screening for sequence type 131 (ST131) 
Based on a previous study it was seen that E. coli isolates (n=6) from Haukeland University 
Hospital all contained IS911 and were typed by multi-locus sequence typing (MLST) to be 
ST131 [33]. A rapid PCR-based method for the detection of the O25b-ST131 clone was 
developed by Olivier Clermont and colleagues [41]. Primers designed to target the 375 bp 
fragment of the pabB gene specifically found in this clone were used. As a positive control of 
the amplification an additional gene, trpA, was included.  
 
The PCR program was performed according to the publication, and also additional 
modifications were made for the second run (Appendix B, table 3). A random sample of 
isolates from collection 1 were screened (n=11) as well as the three AmpC with insertion 
region positive isolates that were from Vestfold (n=2) and Haugesund (n=1). The screening 
was executed according to previously described methods for PCR and gel electrophoresis. 
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PCR conditions and primers are described in Appendix B, table 3-4. The mastermix 
prescription is found in table 8 in Appendix B.  
 
3.3.11 Real- time PCR for the detection of the O25b-ST131 clone 
Real-time PCR both amplifies and quantifies DNA in the same reaction. The PCR machine 
monitors the amplification of a PCR product at every cycle and presents the data in the form 
of an amplification plot. Real-time PCR yields an immediate visual result and no further 
detection methods like agarose gel electrophoresis are required [6]. In this study the dye 
SYBR Green I was used. It fluoresces when bound to double-stranded DNA, which is then 
detected by the PCR machine. After the amplification of the template a melt curve analysis 
was made. When the melting temperature (Tm) is reached, SYBR Green is released and the 
fluorescence decreases.  
 
In a publication by Hiran Dhanji et al. another method for rapid detection of the O25b-ST131 
clone was presented [42]. A specific assay for the allelic variants of the pabB gene is used to 
detect two single nucleotide polymorphisms (SNPs); thymine-144 and adenine-450. For an 
isolate to be characterized as ST131 both of these SNPs need to be present. According to the 
publication melting temperatures of 82.82°C for the “T” assay and 80.69°C for the “A” assay 
are expected [42].  
 
The same sample of isolates from the PCR-based detection of ST131 was used for this study. 
The primer sequences are listed in Appendix B table 4 (ST131AF, ST131AR, ST131TF and 
ST131TR). The mastermix prescription and the PCR conditions are listed in Appendix B table 








1. The real-time PCR machine, ABI 7500 Fast Real-Time PCR Systems, was switched 
on. The controls and the samples were plotted in and the PCR program parameters 
were set.  
2. To the wells of the plate 22.5µl mastermix and 2.5µl template were added. The plate 
was covered with optic tape. 
3. The plate was given a quick spin before added to the machine.  
 
3.4 Pulsed- field gel electrophoresis (PFGE) 
One of the limitations of a standard agarose gel electrophoresis is that it is not able to properly 
separate DNA molecules exceeding 40kb with its constant electrical field. By applying 
multiple electrical fields that alternate, the DNA molecules will move in different directions 
allowing for a separation of up to ~5 Mb in length. The first electrical field starts the process 
by stretching out the coiled DNA molecules. The second field will interrupt the first electrical 
field and the DNA molecules will migrate in a “zigzag” path downwards in the gel. The 
smaller the molecule, the longer the migration in the gel [37].  
 
In order to protect the chromosomes from being fragmented the bacteria are embedded in 
agarose plugs. The cells, while inside the plugs, are treated with lysosome to lyse the cells and 
expose the DNA. The plugs are washed before treated with protinase K, removing DNA 
degrading enzymes naturally present in the cells. The restriction enzyme used, XbaI (New 
England BioLabs, Ipswitch, Ma, USA), will only have a few recognition sites in the genome 
resulting in few fragments. XbaI recognizes the site shown below in figure 4 and creates 
“sticky” ends.  
 





The digested fragments, as well as an appropriate marker, will then be separated on an 
agarose gel by the changing direction of the electric fields applied.  
Isolates included in the PFGE are listed in Appendix A table 3.  
 
Procedure:  
A. Preparation of PFGE plugs: 
1. Lactose agar plates with ampicillin were streaked and incubated over night at 37ºC. 
2. A single bacterial colony was transferred into Falcon tubes with 5ml BHI-media 
(Appendix B, table 6) and incubated overnight at 37ºC with shaking.  
3. 50µl of the culture was transferred into Falcon tubes with 5ml BHI-media and 
incubated at 37ºC for 4 hours with shaking.  
4. The tubes were centrifuged at 3500 rpm for 10 min. 
5. After removing the supernatant, the cells were resuspended in 1ml of cold PIV- buffer 
(Appendix B, table 7)  
6. 495µl of the suspension were transferred to an eppendorf tube where 5µl lysosyme 
(100mg/ml) (Sigma-Aldrich) were added (Appendix B, table 7). The suspension was 
mixed by vortexing and then equilibrated to 50ºC in a water bath.  
7. To each bacterial suspension, 500µl 2% agarose (BioRad) dissolved in PIV-buffer and 
equilibrated to 50ºC (Appendix B, table 7) was added. The suspensions were mixed by 
vortexing before transferred to the plug mould. The plugs were left to solidify for 15 
min at 4ºC.  
8. The plugs were transferred to new tubes containing 2ml lysis buffer (Appendix B, 
table 7) and incubated at 37ºC for 2 hours with slow shaking.  
9. After removing the lysis buffer, the plugs were washed in 1 ml ddH2O for 15 min with 
slow shaking.  
10. After removing the ddH2O, 1ml of ESP buffer containing 50µl/ml proteinase K-
solution (20mg/ml, VWR, West Chester, PA, USA) were added (Appendix B, table 7). 
Incubated at 50ºC in a water bath overnight.  
11. The ESP-solution was removed and the plugs were washed 2x30 min in 1ml TE-buffer 
with slow shaking (Appendix B, table 7). 
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12. The plugs were stored overnight at 4ºC in a thiurea and TE buffer solution (500µl 
thiurea stock solution (Table 7 Appendix B) pr 10ml TE buffer), or until needed for 
use.  
 
B. Restriction enzyme digestion of DNA in agarose plugs 
1. Thin slices of the plugs were cut and transferred to eppendorf tubes. 
2. The slices were washed 2x30 min in TE buffer (table 7 Appendix B), 1x30 min in 
ddH2O, and 1x30 min in 125µl restriction enzyme buffer (Buffer 4, New England 
BioLabs, Ipswitch, Ma, USA) containing bovine serum albumin (BSA) (Appendix B, 
table 7) with slow shaking.  
3. The restriction enzyme mix was prepared. 20U XbaI (New England BioLabs) pr 125µl 
enzyme mix was used (Appendix B, table 7).  
4. The restriction enzyme buffer was removed and 125µl of the restriction enzyme mix 
was added. The slices were incubated at 37ºC overnight with slow shaking.  
5. The plugs were washed 2x30 min in TE buffer (table 7 Appendix B).  
 
C. Gel electrophoresis 
1. Agarose was prepared using 1% Seakem LE agarose (Lonza, Rochland, ME, USA) 
dissolved in 0.5X TBE, boiled in a microwave oven and equilibrated to 50ºC in a 
water bath. 
2. The gel equipment was prepared and the slices were positioned on the gel comb and 
left for some minutes to fully stick to it. The comb was placed and the agarose poured 
into the chamber, a small amount of agarose was kept. The gel was left to solidify for 
30 min at room temperature.  
3. The electrophoresis chamber was filled with 1.8-2 l of 0.5X TBE and the circulation 
was started to cool the system down to 12°C.  
4. After the gel was solidified the comb, as well as access gel, was removed. 
5. A low range PFG marker (New England BioLabs) was included (Appendix B, figure 
2). Slices of the marker were cut and placed directly into the appropriate empty wells 
in the gel.  
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6. The gel was placed in the electrophoresis chamber, the program parameters set (table 
6) and the electrophoresis started. 
 
Table 6. PFGE program parameters 
Program parameters for PFGE 
Pulstime 1-20 sec 
Total runtime 21 hours 
Voltage 6.0 V/cm = 200V 
Angle 120ºC 
Temperature 12 ºC 
Gel running buffer 0.5X TBE 
 
7. The gel was stained in a GelRed solution (Appendix B, table 7) for 60 min after the 
electrophoresis.  
8. The gel bands were visualized using the GelDoc system (BioRad, USA) 
 
D. Interpretations of DNA relatedness 
1. Analysis were made computationally in BioNumerics v6.01 (Applied Maths, Sint-
Martens-Latens, Belgium) using the band-based DICE similarity coefficient and the 
Unweighted Pairs Geometric Matched Analysis (UPGMA). The position tolerance 
was set to 0.5% for optimization and the band comparison was set to 1.0%.  
 
3.5 DNA sequencing  
In this study the Sanger method for DNA sequencing by dideoxy-mediated chain termination 
was used. The method is based on the addition of dideoxynucleotides (ddNTP’s) as well as 
deoxynucleotides (dNTP’s) to the DNA synthesizing reaction. Each ddNTP is labeled with a 
different fluorescent dye that can be detected by a laser beam. During the PCR- program the 
DNA will denature, the sequencing primers will anneal and nucleotides will be incorporated. 
By incorporating a ddNTP instead of a dNTP the extension of the sequence terminates. The 
reason for this being that the absence of a 3´-OH group prevents the formation of a 
phosphodiester bond with the succeeding dNTP. As a result the PCR produces DNA of 
different lengths. The PCR products are separated using capillary electrophoreses and the last 
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ddNTP is detected by recording the different colors from the dyes. Based on this the DNA 
sequence can be determined. The method is quick and simple to use, but the machine has 
problems reading the nucleotides in close range to the sequencing primer. Vague signals can 
be obtained for these regions and there is a need for manual conformation [43]. 
For an optimal sequencing reaction it is important to in advance remove access dNTPs and 
primers from the template after the PCR reaction. The purification is achieved using the two 
hydrolytic enzymes Exonuclease I (Exo) and Shrimp Alkaline Phosphatase (SAP) which 
remove remaining primers and dNTPs, respectively.  
 
In this study DNA sequencing was used for determining the sequences of: 
a. blaAmpC with insertion. 
b. blaTEM. 
c. Quinolone resistance determining regions of parC and gyrA. 
d. MLST: adk, fumC, gyrB, icd, mdh, purA, and recA. 
 
Procedure: 
A. Purification of the PCR product. 
1. 1µl of Exo-SAP (USB, Cleveland, Ohio) was added to each PCR product. The tubes 
were placed in the thermocycler (Applied Biosystems) and the program was started. 
2. Program 
37°C 1 min 
37°C 90 min  
85°C 15 min 
4°C ∞ 






B. Sequencing PCR 
1. The tubes were loaded according to Appendix B table 2. 
2. The PCR thermocycler (Applied Biosystems) was programmed and started (Appendix 
B, table 3) 
3. Nucleotide sequencing was performed at the Sequencing core facility at the University 
of Tromsø using a ABI Prism 3130XL Genetic Analyzer (Applied Biosystems).  
 
C. Sequence analysis 
1. The software package SeqMan II (DNAStar Inc., Madison, WI, USA) was used to edit 
and align the sequences. 
2. BLAST was used in the search of nucleotide sequence homology. BLAST is available 
at the website of the National Center for Biotechnology Information (NCBI) 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi).   
 
3.6 Multilocus sequence typing (MLST) 
MLST is a PCR and sequencing based method developed to determine the clonality of 
bacterial strains. Seven housekeeping gene loci are used to characterize the strains. Each loci 
sequence is given an allelic number and combined they determine the sequence type (ST) of 
the strain. The determination is done by submitting the sequences online to the MLST 
database (http://mlst.ucc.ie/mlst/dbs/Ecoli) and a ST is generated. The E. coli MLST scheme 
uses internal fragments of the following seven house-keeping genes: 
 
1. adk : adenylate kinase 
2. fumC: fumarate hydratase  
3. gyrB: DNA gyrase  
4. icd: isocitrate/isopropylmalate dehydrogenase  
5. mdh: malate dehydrogenase  
6. purA: adenylosuccinat dehydrogenase  
7. recA: ATP/GTP binding motif  
43 
 
In this study the sequence types were determined for collection 3. The PCR and sequencing 
reaction were performed according to previously described methods. Mastermix, primers and 
PCR programs are described in Appendix B, table 1-4. Sequence analysis were performed 
using SeqMan II (DNAStar Inc., Madison, WI, USA).  
 
3.7 Designing primers using primerBlast 
For the sequencing of the inserts in the blaAmpC region the primers available (AmpCF and 
AmpCintR) were not sufficient for covering the whole region. Additional internal primers 
were designed using primerBLAST (http://www.ncbi.nlm.nih.gov/tools/primer-
blast/index.cgi?LINK_LOC=BlastHome). These were named IS911 1F, IS911 5F, IS911 2R 
















4.1 General analysis  
The study by Igeltjørn showed that IS911 elements linked to blaAmpC were found in 5 isolates 
of E. coli submitted to K-res from the time period 2005-2007 [33]. Of these, 4 isolates were 
clonally related and received at K-res from Haukeland University Hospital indicating a local 
spread of these isolates. To investigate this further an extensive data mining process was 
performed on all isolates submitted to K-res covering the years 2006-2010 from Norwegian 
clinical microbiology laboratories. As the assumption was that the IS911-blaAmpC linkage was 
specific for isolates from the Bergen region a control group of isolates from other clinical 
microbiology laboratories in Norway was required. All isolates with the profile 
“Chromosomal AmpC with or without impermeability” were registered. In total, 360 isolates 
were registered for the study. The laboratory distribution of isolates over the time period 
indicated that the majority of isolates received at K-res were from Haukeland (n=111) (figure 
5), followed by Østfold Hospital (n=50), Vestfold Hospital (n=37), and Sørlandet Hospital 














































































































































































































































































Figure 5. Graphical overview of the laboratory distribution of E. coli isolates with the profile 




4.1.2 Distribution analysis  
All the 111 isolates from Haukeland were screened for insertion in the AmpC region using the 
primers AmpCF and AmpCintR listed in table 4, appendix B. In total, 46 of the isolates 
screened positive for an insertion into the AmpC region while 64 were negative (table 7, 
figure 6). Overall, an increase in the ratio of positive isolates compared to negative isolates 
over the years was observed. The lowest ratio was observed in 2007 with only 3 positive 
isolates compared to 40 negative (~7%), while the highest ratio was seen in 2009 with 14 
positive isolates versus 1 negative (~93%). The total number of isolates ranged from 6 to 43, 
with 43 isolates registered in 2007 compared to only 6 in 2010. One isolate did not give a 
PCR product and the screening was repeated with the same result.  
 
Table 7. Chromosomal AmpC hyperexpressing E. coli isolates from Haukeland University 
Hospital ranged according to year received at K-res and whether they are positive or negative 
for an insertion into the AmpC region.  
Haukeland hospital 
 2006 2007 2008 2009 2010 Total 
Insertion Positive 8 3 17 14 4 46 
Insertion Negative 16 40 5 1 2 64 
No PCR product 1 - - - - 1 































Figure 6. Graphical overview of the distribution among the Haukeland isolates of insertion 
positive (green) and insertion negative (red) isolates.  
 
To investigate if whether an insertion into the AmpC region was also found in other parts of 
the country a control group of 100 isolates from a variety of Norwegian clinical microbiology 
laboratories were screened using the same primers, AmpCF and AmpCintR (Table 4, 
Appendix B). In contrast to the Haukeland screening only 3 isolates were AmpC with an 
insertion region-positive, while 97 screened negative (table 8). These isolates were from 
Vestfold Hospital (n=2) and Haugesund Hospital (n=1).  
 
Table 8. Chromosomal AmpC hyperexpressing E. coli isolates from various Norwegian 
laboratories ranged according to year received at K-res and whether they are positive or 
negative for an insert into the AmpC region.  
Various Norwegian laboratories (control group) 
 2006 2007 2008 2009 2010 Total 
Insertion Positive 0 0 1 2 0 3 
Insertion Negative 20 20 19 18 20 97 




Most of the bacterial isolates were collected from urine samples (n=185) followed by blood 
culture (n=11), abscess (n=4), pus (n=3), and secretion (n=3). Three specimen categories; 


























































Figure 7. Graphical overview of the distribution of materials the E. coli isolates from 









The isolates received at K-res from the Department of Microbiology at Haukeland University 
Hospital can originate from a range of locations. Some are from inpatients at different 
departments within the hospital while others originate from outpatients with samples taken at 
a general practice or in a nursing home. For the 46 positive isolates the main location of origin 
was Nursing Home 1 (n=14) followed by Nursing Home 2 (n=7) (figure 8). The 46 positive 
isolates were divided into 13 locations, where the two hospitals, Hospital 1 and Hospital 2, 



























































































Figure 8. Graphical display of the distribution of originating locations of the isolates positive 
for an insertion into the AmpC region received at K-res from Haukeland University Hospital. 






As the study progressed it was discovered that some bacterial isolates were derived from the 
same patient (table 9). A complete investigation was not performed on the strain collections.  
 
Table 9. Overview of the patients with two- or more isolates, their location and date received 
at K-res. Marked in green are the isolates with an insertion into the AmpC region, while in red 
are the isolates with no insertion in the AmpC region.  
Patient Isolate Location Received 
(d-m-y) 
A K29-77 Hospital 2 31-01-06 
K29-80 Nursing Home 2 03-02-06 
K30-44 Nursing Home 4 15-03-06 
B K30-36 General Practice 3 03-03-06 
K36-03 Nursing Home 5 06-11-06 
C K44-51 General Practice 7 06-06-07 
K45-29 General Practice 7 10-07-07 
D K44-54 Nursing Home 6 06-06-07 
K44-60 General Practice 4 12-06-07 
E K45-41 General Practice 5 16-07-07 
K45-48 General Practice 5 18-07-07 
F K46-48 Hospital 2, Surgical ward 04-10-07 
K46-58 Hospital 2, Surgical ward 15-10-07 
G K48-48 General Practice 2 06-03-08 
K54-42 General Practice 2 06-02-09 
H K49-14 Nursing Home 1 07-05-08 
K53-65 Nursing Home 1 12-08-08 
I K52-78 Hospital 1, Heart post 10-11-08 
K53-43 Hospital 1, Heart post 11-11-08 
J K49-70 General Practice 2 15-07-08 









4.2 Molecular results  
4.2.1 PFGE analysis  
32 isolates were selected for PFGE analysis, including collection 3 (n=12) and a random 
selection of isolates with an insertion in the AmpC region from Haukeland University 
Hospital (n=20), listed in table 3, Appendix A. Two cases of one patient with multiple isolates 
were included in the study to investigate for changes over the time period (Patient A: K29-77, 
K29-80, and K30-44, Patient B: K30-36 and K36-03).  
 
All the Haukeland isolates cluster together in one large cluster with an overall similarity of 
61%, and are divided into several sub clusters (figure 9). The three non-Haukeland isolates 
cluster together in a separate cluster with a similarity of 54%, the two Vestfold isolates being 
the most similar (74%).  
 
A total of six clusters were discovered with 85% similarity all harboring isolates from a 
variety of locations and years of isolation. A larger cluster of isolates from 2006 was observed 
including the isolates; K29-80, K34-08, K30-24, K29-77, K30-36, and K36-03, marked “C3” 
in figure 9. The two isolates in cluster 4 are from the same location, Nursing Home 1, but 
from different years (2007 and 2008). Cluster 6 contains 3 isolates from the same year, 2009, 
from two locations; Hospital 2 and Nursing Home 2.  
 
Overall, the Haukeland isolates are distributed more or less evenly throughout the sub clusters 
both considering the year of isolation and the location of origin. When looking into the 
originating locations of the Haukeland isolates the majority was from Nursing Home 1 
(n=10), also seen as the major contributor on an overall basis (figure 8), followed by Hospital 
2 and Nursing Home 2 with 5 isolates each. Two isolates K29-80 and K34-08 had identical 
PFGE profiles. They were both from the same year, 2006, but from different locations; 
Nursing Home 2 and Nursing Home 1, respectively. During the study it was discovered that 
one patient might have several samples registered, and two of these patients were included in 
the PFGE (table 9). Patient A with the isolates K29-77, K29-80 and K30-44 were not 
identical. K29-77 and K29-80 clustered closer together in cluster 3 and have an extra band 
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compared to K30-44 (cluster 5). They were all from 2006, but from distinct locations; 
Hospital 2, Nursing Home 2, and Nursing Home 4. The isolates from patient B, K30-36 and 
K36-03, cluster closely together in cluster 3, only separating them by one band. They are from 
different locations; General Practice 3and Nursing Home 5, but from the same year, 2006. 
 












Figure 9. Dendogram illustrating the genetic relatedness of 32 isolates with an insertion in the 
AmpC region examined by pulsed-field gel electrophoresis (PFGE). Analysis was made using 
BioNumerics v6.01 (Applied Maths, Sint-Martens-Latens, Belgium). K29-77 was used as a 
control for the second PFGE run and is therefore listed twice. Major clusters defined by PFGE 






4.2.2 Sequence type analysis; PCR, Real-time PCR, and MLST  
Two previously described rapid methods; one PCR-based method and one Real-time PCR 
method directed at identifying the O25b-ST131 clone were investigated. 
 
The PCR-based screening for ST131, described by Olivier Clermont and colleagues, targeted 
the pabB gene of 375bp and a control gene of the amplification, trpA of 427bp (primers are 
listed in table 4, Appendix B) [41]. For an isolate to be ST131-positive two distinct bands, 
one for each gene mentioned above, would be seen on an agarose gel after electrophoresis. In 
this study the bands visible on the gel were not as clearly defined as described in the 
publication. The negative control strain, E. coli A-81 (ATCC 25922), also had a band for the 
ST131-determining gene. This band was not as strong and clear as for the positive control. 
The study was repeated including isolates with known sequence types as negative controls 
(K34-04: ST117, K20-72: ST127, K05-20: ST359, K26-35: ST636, and K33-69: ST976) [44] 
and increasing the annealing temperature with 2°C (67°C). However, a band for pabB was 
observed in all these isolates.  
 
The Real-time PCR screening method was directed at two single nucleotide polymorphisms 
(SNPs), thymine-144 and adenine-450, described in a publication by Hiran Dhanji et al.[42]. 
For an isolate to be of ST131 both the SNPs need to be present. ST131-positive isolates are 
determined based on melt curve analysis where the melt temperatures of 82.82°C (“T”-assay) 
and 80.69°C (“A”-assay) are stated in the paper. In this study the melting temperatures of the 
positive and negative isolates were too close to determine the sequence types of the samples. 
None of the temperatures came close to the expected values of 82.82°C (“T”-assay) and 
80.69°C (“A”-assay), instead they were ranging from about 75°C-78°C for both assays. The 
study was repeated with the same results.  
 
Collection 3 was therefore typed by the standard multi-locus sequence typing (MLST) scheme 
as described by Achtman et al. [45]. The allelic profiles of the isolates as well as the sequence 




Table 10. Sequence types determined for collection 3. The allelic numbers for each gene of 
the isolates are listed in the table.  
  MLST genes  
Hospital Isolate adk fumC gyrB icd mdh purA recA Sequence 
type (ST) 
Haukeland K29-48 53 40 47 13 36 28 29 ST131 
K30-44 53 40 47 13 36 28 29 ST131 
K47-31 53 40 47 13 36 28 29 ST131 
K48-26 53 40 47 13 36 28 29 ST131 
K53-47 53 40 47 13 36 28 29 ST131 
K57-52 53 40 47 13 36 28 29 ST131 
K58-13 53 40 47 13 36 28 29 ST131 
K63-77 53 - 47 13 36 28 29 - 
K68-26 53 40 47 13 36 28 29 ST131 
Haugesund K61-43 6  4 12 1 20 13 7 ST23 
Vestfold K52-15 35 37 29 25 4 5 73 ST405 
Vestfold K71-61 35 37 29 25 4 5 73 ST405 
 
All but one of the isolates from Haukeland University Hospital belonged to sequence type 
131. One of the Haukeland isolates, K63-77, did not give a PCR-product of the gene fumC. 
The PCR was repeated without any results. An additional reverse primer was used, fumCR1 
(Appendix B, table 4), as mutations can occur in the primer-binding region. Still no product 
was obtained. Although the allelic variants of the other genes were identical to ST131 the 
sequence type for this isolate could not be determined. The two isolates from Vestfold both 
belonged to ST405, while the isolate from Haugesund belonged to ST23. 
 
The ST131 determined isolates from Haukeland University Hospital can be found in all sub 
clusters of the PFGE dendogram (figure 7), apart from cluster 3 and 4. This indicates a large 







4.2.3 Sequencing and analysis of the blaAmpC with an insertion region  
The AmpC with an insertion region was sequenced and analyzed for all isolates in collection 
3 using the primers AmpCF and AmpCintR for the screening process and also the IS911 
specific primers IS911 1F, 2R, and 5F, and the IS911 primer 4R (which binds in the AmpC 
region), (Table 4, Appendix B) for the sequencing of the region.  
 
The nucleotide sequences from the nine isolates derived from Haukeland University Hospital 
were aligned against each other and were 100% identical. They were also aligned against 
reference sequences for IS911 (AY555729.1) and AmpC (AY899338.1) in the ClustalW 
program (Figure 1 Appendix C) with 100% nucleotide identity to the reference sequences.  
 
Analysis of the sequence showed that IS911 was inserted 11 bp upstream of the wild type -10 
box between position -25 and -24 (figure 10). The changes resulted in a 17 bp distance 
between the -10 box and the IS911 specific sequence TTGACC, thought to act as a -35 box. 
The changes in the promoter region are likely driving the hyperexpression of the blaAmpC 
gene. The insertion of the IS-element created duplications at position -22 to –24. The IS911 
element’s insertion into the chromosome was at the same place, and its structure and length 
identical to what described in a Canadian study [14]. 
 
Sequencing of the three isolates from other locations than Haukeland, Vestfold and 
Haugesund, did not result in a complete sequence with the selected primers. The AmpC 
primers, AmpCF and AmpCintR, gave a sequencing product, but resulted in unclosed poor 
sequences. Out of the four primers designed for this study all but one, IS911 4R, failed to give 
a sequencing product. This primer was located in the blaAmpC-region and not in the IS911 
region. BLAST searches with the sequences available all indicated the presence of IS10 and 
not IS911 in these isolates. The IS10 element is of about the same size as IS911 (1329 bp 
versus 1250 bp, respectively). The PCR product using the primers AmpCF and AmpCintR in 





To verify that blaAmpC was linked to IS911 in the Haukeland isolates, 28 isolates, both from 
Haukeland (n=25) and non-Haukeland (n=3), isolates were screened for the linkage of IS911 
with blaAmpC. The primers IS911-1F and IS911-4R were used (Appendix B, table 4). The 
three non-Haukeland isolates (K52-15, K71-61, and K61-43) gave no PCR product as 
expected, while the isolates from Haukeland all gave a positive PCR product linking IS911 















4.2.4 Antimicrobial susceptibility profile  
An extended antimicrobial susceptibility profile of collection 3 was determined. To 
investigate possible co-resistance a fluoroquinolone, ciprofloxacin, and aminoglycosides; 
tobramycin, gentamicin, and amikacin were included (table 11). The other MIC values were 
collected from previous analysis by K-res during the data mining process. The list was 
supplemented with antimicrobial susceptibility testing were results were lacking.  
 
All of the isolates are I and/or R to the β-lactam antimicrobial agents with the exception of the 
carbapenems. Among the penicillins all isolates showed high-level resistance towards 
ampicillin, as well as resistance to amoxicillin-clavulanate. Eight isolates were susceptible to 
piperacillin-tazobactam while remaining isolates were intermediate susceptible. For the 
cephalosporins, high-level resistance was observed against cefoxitin, an indicator for AmpC-
hyperexpression. All the Haukeland isolates were resistant to cefotaxime and ceftazidime with 
the exception of K48-26 that was intermediate susceptible to cefotaxime and K57-52 that 
were intermediate susceptible to both cefotaxime and ceftazidime. In contrast, only the isolate 
from Haugesund was resistant to ceftazidime out of the three non-Haukeland isolates. For the 
monobactam aztreonam the MIC value range was from 4-32 mg/L with four intermediate 
susceptible isolates, K29-48, K52-15, K71-61, and K63-77, and the rest being resistant. MIC 
values for the carbapenem meropenem were low and all isolates were susceptible. With 
respect to non-β-lactams all isolates were resistant to ciprofloxacin, tobramycin, and 
gentamicin, but susceptible to amikacin. For Trimethoprim-Sulfamethoxazole the MIC range 
was from 0,0625 to >32 mg/L, with 9/12 isolates with a MIC >32 mg/L. With respect to the 
antimicrobial agents specifically used for urinary tract infections all isolates were susceptible 
to mecillinam and two isolates, K71-61 and K68-26, were resistant to nitrofurantoin and 



















































































































































































































































































































































































































































































































































































Table 11. Antimicrobial 

















TS: Trimethoprim- Sulfamethoxazole 
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4.2.5 blaTEM  
All isolates of collection 3 were screened for blaTEM using the primers blaTEM –FTW and 
blaTEM –R mod TW listed in table 4, Appendix B. All isolates were positive for TEM and were 
therefore sequenced using the same primers. BLAST searches showed that all isolates 
harbored blaTEM-1.  
 
4.3 Multi-resistance analysis 
As the isolates showed co-resistance to ciprofloxacin and the aminoglycosides tobramycin 
and gentamicin they were investigated for the presence of aac(6’)-Ib-cr and mutations in the 
QRDR. 
 
4.3.1 AAC(6`)-Ib-cr analysis 
The isolates were screened for the gene encoding the aminoglycoside modifying enzyme 
AAC(6`)-Ib-cr using the primers aac(6`)-Ib-F and aac(6`)-Ib-R (table 4, Appendix B). All 
isolates screened negative for the gene. 
 
4.3.2 Quinolone resistance determining region (QRDR) analysis  
The Quinolone resistance determining regions parC and gyrA were sequenced using the 
primers parCF, parCR, gyrA6, and gyrA631R (table 4, Appendix B).  
 
The DNA sequences of the QRDR were translated into protein sequence and aligned with 
reference sequences for ParC (NP_417491) and (GyrA NP_416734) using the ClustalW 
program to investigate for mutations known to confer ciprofloxacin resistance. The ClustalW 
alignments are found in Appendix C, figure 2 for gyrA and figure 3 for parC. All isolates 
harbored one or two mutations for both of the genes (table 12). The isolates therefore have 
from three to four mutations all together, where the amino acid changes are all previously 
described in the literature [27]. All of the Haukeland isolates have the same mutations for 
both of the genes. In the isolate from Haugesund only one mutations is found in parC, but has 
apart from this identical mutations compared to the Haukeland isolates. The isolates from 
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Vestfold both harbored two mutations in both of the genes. Only one mutation, Y87D in gyrA 
differ these isolates from Haukeland.  
 
Table 12. Mutations in the Quinolone resistance determining region (QRDR) for parC and 
gyrA determined after a ClustalW alignment against reference sequences (ParC NP_417491 
and GyrA NP_416734).  
 QRDR mutations 
Hospital Isolate parC gyrA 
Haukeland K29-48 I80S, V84E L83S, N87D 
K30-44 I80S, V84E L83S, N87D 
K47-31 I80S, V84E L83S, N87D 
K48-26 I80S, V84E L83S, N87D 
K53-47 I80S, V84E L83S, N87D 
K57-52 I80S, V84E L83S, N87D 
K58-13 I80S, V84E L83S, N87D 
K63-77 I80S, V84E L83S, N87D 
K68-26 I80S, V84E L83S, N87D 
Haugesund K61-43 I80S L83S, N87D 
Vestfold K52-15 R80S, V84E L83S, Y87D 
Vestfold K71-61 R80S, V84E L83S, Y87D 
* Arg/R: Arginine, Asn/N: Asparagine, Asp/D: Aspartic acid, Glu/E: Glutamic acid, Ile/I: 














E. coli naturally produce small amounts of the chromosomally encoded β-lactamase AmpC. 
The expression of blaAmpC is noninducible and regulated by a weak promoter and an 
attenuator. Insertion sequence (IS) elements inserted into the promoter region have been 
described as one reason for the hyperexpression of blaAmpC conferring resistance to penicillins 
and cephalosporins, except 4
th
 generation cephalosporins.  
 
5.1 General discussion  
Overall, there is a higher number of E. coli isolates with a profile of hyperproduction of the 
chromosomal AmpC received at K-res from Haukeland University Hospital (n=111) from 
2006-2010 than any other Norwegian clinical microbiology laboratory. This could indicate 
higher incidents of chromosomal AmpC from the Bergen area or differences in the number of 
isolates referred to K-res. This could reflect differences in their routines of referring isolates 
to K-res or internal methods for detection of isolates with an AmpC profile. When looking 
into the yearly distribution of the chromosomal AmpC E. coli isolates received from 
Haukeland the numbers each year show great variability. In 2007 43 isolates were registered 
while only 6 in 2010. This could be a result of changing procedures for the reporting of 
questionable isolates to K-res and does not necessarily mean a reduction in cases. The criteria 
for referring isolates to K-res also changed during the period to exclude isolates without co-
resistance to other antimicrobial agents such as aminoglycosides, ciprofloxacin, trimethoprim-
sulphametoxazole, and nitrofurantoin (www.unn.no/kres).  
 
Nursing Home 1 was indicated as the main location of origin of the Haukeland AmpC with an 
insertion region positive isolates (figure 6). As the numbers of duplicate isolates are not taken 
into consideration for the study, the distribution of originating locations might alter. The 
routines of the differing locations regarding the reporting of questionable isolates to 
Haukeland University Hospital are also unknown and important factors. How many samples 
each nursing home or general practice sent in during the time period 2006-2010 is not known. 
The occurrence of the clone might be more evenly distributed among the location than this 




As previously discovered by Igeltjørn E. coli isolates from Haukeland University hospital 
harbored an IS911 element inserted into the AmpC region [33]. After a screening of the 
AmpC region of the 111 Haukeland isolates a total of 46 isolates proved to have an insertion 
in this region. Compared to the control group of non-Haukeland isolates only three had an 
insertion region in the AmpC gene. The numbers highly indicate a region-specific bacterial 
feature. A sample of the positive Haukeland isolates was screened specifically for IS911 
insertion in the AmpC region, which they all were positive for. This indicates that this 
element is present in all the Haukeland isolates with an insert. The insertion of an element in 
the promoter region of the AmpC gene has been observed in several cases leading to the 
hyperexpression of the β-lactamase. Insertion elements like IS10, ISEc10, IS2, and IS911 
have all been observed executing the same function [14, 21, 46].  
 
In this study it was discovered that IS911 was inserted between the -35 box and the -10 box in 
the promoter region, hence creating an alternative and stronger promoter compared to the wild 
type. The IS911 in the Haukeland isolates were inserted between position -24 and -25 also 
described in cefoxitin resistant isolates from E. coli in a Canadian study [14]. The 
hyperproduction of blaAmpC is reflected on the MIC values for the isolates particularly for 
cefoxitin which is an indicator for hyperproduction.  
 
The three non-Haukeland isolates (Vestfold n=2, Haugesund n=1) were also positive for an 
insertion region in the AmpC promoter region. Optimal primers for this region were not 
available as the insertion region proved to be different compared to the Haukeland isolates. 
BLAST searches revealed another IS-element, IS10. This element is also described in E. coli 
from a Canadian study [14]. The finding of IS10 in the non-Haukeland isolates also support 
the hypothesis that there is a regional spread of IS911-blaAmpC isolates in the Bergen region. 
IS10 belongs to a different IS family than IS911, family 4, and forms a part of the composite 
tetracycline resistance transposon Tn10 [47]. 
 
During the study 10 cases were discovered where one patient had several bacterial samples 
registered. This was not investigated closer into so the possibility of more duplicate or 
triplicate isolates is likely, and its occurrence was not taken into consideration for the study. A 
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precaution is therefore needed when interpreting the results. A total accuracy in the numbers 
of isolates can only be achieved after a thorough look into the patient registers at Haukeland 
University Hospital. Patient transfer between institutions also complicates the analysis as for 
some patients samples have been submitted from different institutions (table 9). However, the 
findings of the same clone in the same patient indicate long term colonization that could be 
important with respect to reinfection and further spread.  
 
MLST analysis confirmed that the isolates derived from Haukeland University Hospital 
belonged to ST131. One of the isolates, K63-77, did not give a PCR product for one of the 
genes, fumC, and the sequence type could not be determined. Nevertheless, this isolate 
resembles the other isolates from Haukeland for the six other genes used for the MLST. 
Depending on the degree of mutations in the fumC gene, one can assume that K63-77 is of the 
same ST as the rest of the Haukeland isolates or a single locus variant.  
 
ST131 is a globally disseminated multi-drug resistant E. coli clone associated with urinary 
tract and blood stream infections [30]. The specimen distribution for this study reflects this 
with the highest prevalence of urine samples (n=185) followed by blood culture (n=11).  
 
The ST131 clone has been described in a wide range of locations including hospitals, long-
term facilities and in the community [30]. The locations of the isolates for this study were 
found to include both several departments within two hospitals, Hospital 1 and Hospital 2, 
several general practices and nursing homes. The clone is not limited to one location making 
its spread more worrisome.  
 
ST131 is associated worldwide with the spread of ESBLs of the CTX-M family, especially 
CTX-M-15 [32, 48]. It has been found to be associated with ciprofloxacin resistance in eight 
European countries [49] and CMY-2 production in Norwegian isolates [44]. The clone has not 
only been identified in patients but also from stool samples from healthy individuals in France 
[50]. ST131 is as well identified in companion animals and poultry, including the possibility 
of transmission through animal contact and food consumption [51].  
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The regional spread of the ST131 clone in the Bergen region is to date mainly associated with 
the hyperexpression of chomosomal blaAmpC. As the worldwide disseminated ST131 clone is 
often found to hold ESBLs, particularly CTX-M-15, there is a high likelihood for the transfer 
of resistance mechanisms by horizontal gene transfer, increasing the resistance profile of the 
Bergen clone.  
 
XbaI-PFGE-types of ST131 isolates have previously been shown to be diverse, as also 
discovered in this study [32]. All isolates from Haukeland University Hospital clustered 
together with an overall similarity of 61%. This indicates a genetic diversity within the 
sequence type and cause difficulties identifying the clones. This problem was also recognized 
by Olivier Clermont et al. describing the difficulty of recognizing members of the O25b-
ST131 clone as PFGE patterns are varying within a similarity of ≥60% [41].  
 
The three non-Haukeland isolates were unrelated to ST131 and belonged to ST405 (Vestfold) 
and ST23 (Haugesund). ST405 is part of a larger sequence type complex (STC405), and also 
a sequence type associated with the global dissemination of CTX-M-15 [52]. It has been 
identified in a Norwegian study harboring other CTX-M variant such as CTX-M-3 and CTX-
M-14 [32]. Naseer et al. characterized a novel single locus variant of ST405, namely ST964, a 
sequence type also associated with CTX-M-15 [32].  
 
ST23 belongs to a larger complex, STC23, also including ST90, ST88, and ST650. In a 
Spanish study several of the sequence types of STC23 were associated with the dispersal of 
CTX-M variants [53].  
 
Two cases of patients with more than one bacterial isolate were included in the PFGE study. 
For both patients changes in the PFGE profiles were observed. Patient A had three isolates 
K29-77, K29-80, and K30-44, where all were sampled with about a month apart. The isolates 
K29-77 and K29-80 cluster together in cluster 3, while K30-44 belongs to cluster 5. K30-44 
was isolated last and is lacking one gel band compared to the other two isolates. Patient B had 
two isolates, K30-36 and K36-03, isolated eight months apart. Both isolates cluster together in 
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cluster 3, but a one band change is seen. Isolate K36-03 has one extra gel band and was 
isolated last of the two. The small changes observed of either loosing or acquiring a gel band 
indicate that the bacteria have evolved over time.  
 
The blaTEM-1 was identified in all isolates of collection 3. This is a plasmid encoded enzyme 
commonly found in Enterobacteriaceae. The enzyme confers resistance to penicillins like 
ampicillin, ticarcillin, and piperacillin, and narrow-spectrum cephalosporins, like cephalothin 
or cefazolin. For this study the TEM-1 enzyme was not a great contributor to the 
antimicrobial resistance profile as the isolates would be resistant to the same and more 
antimicrobial agents by the hyperexpression of AmpC. ESBLs derive from amino acid 
substitutions of, among others, TEM-1 resulting in resistance to oxyimino-beta-lactam 
substrates, like ceftazidime, ceftriaxone, and cefepime. If the isolates of the study had 
harbored other TEM-types, ESBLs, resistance against also 4
th
 generation cephalosporins may 
have been observed [54].  
 
5.2 Multi-resistance 
Quinolones have a wide spectrum of activity and have been extensively used and misused in 
both human and veterinary medicine, leading to the emergence and spread of resistant strains. 
The fluoroquinolone ciprofloxacin has been pointed out as the most consumed antimicrobial 
agent worldwide [55], and the ST131 clone is associated with the spread of fluoroquinolone 
resistance [32, 56]. Alterations in the quinolone targets, DNA gyrase and topoisomerase IV, is 
one of the mechanisms of resistance described in the literature. Single mutations in gyrA have 
been described to result in high-level resistance to nalidixic acid. In order to obtain high-level 
resistance to fluoroquinolones additional mutations are needed in the same gene and/or in 
another target such as parC [28].  
 
Mutations in both parC and gyrA were observed for all strains of collection 3. The Haukeland 
isolates had the following mutations for parC; I80S and V84E, and for gyrA; L83S and 
N87D. The isolate from Haugesund had one mutation in parC, I80S, and two in gyrA, L83S 
and N87D. The two isolates from Vestfold had two mutations for both of the genes, parC; 
R80S and V84E, and for gyrA; L83S and Y87D. All the above mentioned mutations are 
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described by Ruiz as quinolone resistance conferring changes. As described, the most 
frequent mutations seen for E. coil in gyrA are, as discovered by this study, at the codons 83 
and 87. For parC the most commonly observed mutations are at codons 80 and 84 [28]. This 
is in accordance to the mutations observed in this study, explaining the high-level resistance 
to ciprofloxacin.  
 
Resistance to the fluoroquinolone ciprofloxacin may also be conferred by the aminoglycoside 
modifying enzyme AAC(6`)-Ib-cr. Screening of collection 3 proved that none of the isolates 
harbor this enzyme. The high-level resistance observed to ciprofloxacin may therefore be 
caused solely by the multiple mutations in the target regions, DNA gyrase and topoisomerase 
IV, or the presence of qnr-genes. As the isolates also were resistant to the aminoglycosides 
tobramycin and gentamicin, this resistance may be caused by other aminoglycoside modifying 
















6. Concluding remarks 
The results indicate that there is a successful spread of an E. coli ST131 clone with an IS911-
associated hyperexpressing blaAmpC in the Bergen region. As this specific clone or the 
blaAmpC-IS911 linkage was not identified in other Norwegian isolates further supports the 
regional location of this spread and that this is an unusual profile among Norwegian isolates. 
The only isolates with an insertion in the chromosomal blaAmpC region harboring IS10 instead 
of IS911 were identified in two different Norwegian counties, Vestfold and Rogaland.  
 
The clonal spread of this clone in the Bergen region should be monitored and investigated 
further. As a start an investigation into the patient registers at Haukeland University Hospital 
should be executed in order to get an overview of the number of isolates from the same 
patient. As Nursing Home 1 was pointed out as the main originating location of this clone it 
would be interesting visiting the location for a closer look into its hygiene routines and its 
connections to general practices, hospitals and other nursing homes. The route of transmission 
could then more easily be determined in order to control the spread.  
 
The finding that the blaAmpC-IS911 linkage isolates belonged to ST131 should raise concerns 
considering its widespread occurrence and multi-resistance highly virulent uropathogenic 
profile. The co-resistance profile observed in the Haukeland isolates with resistance to 
ciprofloxacin, gentamicin, tobramycin, and trimethoprim-sulfamethoxazole is worrying in this 
aspect. Further studies are needed in order to determine the aminoglycoside resistance 
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Table 1. Bacterial isolates in strain collection 1 (Haukeland University Hospital n=111) and 2 
(other hospitals n=100).  
  2006           
Number  K-res number Received Hospital Material Specie Comments 
1 K29-48 291205 Haukeland Urine E.coli 
 2 K29-53 301205 Haukeland Urine E.coli 
 3 K29-74 270106 Haukeland Urine E.coli 
 4 K29-77 310106 Haukeland Blood culture E.coli Same patient as K29-80 and K30-44 
5 K29-80 030206 Haukeland Urine E.coli Same patient as K29-77 and K30-44 
6 K29-81 030206 Haukeland Urine E.coli 
 7 K30-1 030206 Haukeland Urine E.coli 
 8 K30-20 200206 Haukeland Urine E.coli 
 9 K30-23 270206 Haukeland Urine E.coli 
 10 K30-24 270206 Haukeland Urine E.coli 
 11 K30-25 270206 Haukeland Urine E.coli 
 12 K30-35 030306 Haukeland Urine E.coli 
 13 K30-36 030306 Haukeland Urine E.coli Same patient as K36-3 
14 K30-44 150306 Haukeland Urine E.coli Same patient as K29-77 and K29-80 
15 K30-58 040406 Haukeland Urine E.coli 
 16 K30-60 070406 Haukeland Urine E.coli 
 17 K33-03 090506 Haukeland Urine E.coli  
18 K33-14 230506 Haukeland Urine E.coli 
 19 K33-19 290506 Haukeland Urine E.coli 
 20 K34-8 230806 Haukeland Urine E.coli 
 21 K34-25 060906 Haukeland Urine E.coli 
 22 K34-34 140906 Haukeland Urine E.coli 
 23 K34-70 201006 Haukeland Urine E.coli 
 24 K36-3 061106 Haukeland Urine E.coli Same patient as K30-36 
25 K36-17 201106 Haukeland Urine E.coli 
 26 K29-27 151205 Stavanger Universitetssykehus Urine E.coli  
27 K30-18 200206 Sykehuset i Vestfold Urine E.coli  
28 K30-29 200206 Sykehuset Østfold Urine E.coli  
29 K30-57 300306 Sykehuset Østfold Urine E.coli  
30 K30-81 020506 Rikshospitalet Urine E.coli  
31 K33-01 080506 Sykehuset Østfold Urine E.coli  
32 K33-09 180506 Rikshospitalet Urine E.coli  
33 K33-16 230506 Sykehuset i Vestfold Urine E.coli  
34 K33-71 250706 UNN Urine E.coli  
35 K34-10 230806 Sykehuset i Vestfold Puss E.coli  
36 K34-15 290806 UNN Pressure wound E.coli  
37 K34-23 061106 Sykehuset Innlandet Urine E.coli  
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38 K34-32 121106 Sykehuset Østfold Urine E.coli  
39 K34-36 180906 Sørlandet Sykehus Urine E.coli  
40 K34-60 091006 Stavanger Universitetssykehus Urine E.coli  
41 K36-01 061106 Sykehuset i Vestfold Urine E.coli  
42 K36-05 101106 UNN Urine E.coli  
43 K36-09 161106 Sykehuset Østfold Urine E.coli  
44 K36-10 161106 Sykehuset Innlandet Urine E.coli  
45 K36-13 161106 Ullevål BAL E.coli  
  2007           
Number  K-res number Received Hospital Material Specie Comments 
46 K36-40 221206 Haukeland Urine E. coli 
 47 K41-11 070207 Haukeland Urine E. coli 
 48 K41-22 020307 Haukeland Blood  E. coli 
 49 K41-33 160307 Haukeland Urine E. coli 
 50 K41-34 190307 Haukeland Blood E. coli 
 51 K41-39 220307 Haukeland Urine E. coli 
 52 K41-46 280307 Haukeland Urine E. coli 
 53 K41-52 300307 Haukeland Urine E. coli 
 54 K41-61 120407 Haukeland Urine E. coli 
 55 K41-81 260407 Haukeland Urine E. coli 
 56 K44-26 210507 Haukeland Urine E. coli 
 57 K44-50 060607 Haukeland Urine E. coli 
 58 K44-51 060607 Haukeland Urine E. coli Same patient as K45-29 
59 K44-52 060607 Haukeland Urine E. coli 
 60 K44-53 060607 Haukeland Urine E. coli 
 61 k44-54 060607 Haukeland Urine E. coli Same patient as K44-60 
62 K44-60 120607 Haukeland Urine E. coli Same patient as K44-54 
63 K44-63 140607 Haukeland Urine E. coli 
 64 K44-64 140607 Haukeland Urine E. coli 
 65 K44-70 220607 Haukeland Urine E. coli 
 66 K44-77 270607 Haukeland Urine E. coli 
 67 K44-78 270607 Haukeland Urine E. coli 
 68 K45-23 020707 Haukeland Urine E. coli 
 69 K45-24 020707 Haukeland Urine E. coli 
 70 K45-29 100707 Haukeland Urine E. coli Same patient as K44-51 
71 K45-40 160707 Haukeland Urine E. coli 
 72 K45-41 160707 Haukeland Urine E. coli Same patient as K45-48 
73 K45-48 180707 Haukeland Urine E. coli Same patient as K45-41 
74 K45-59 020807 Haukeland Urine E. coli 
 75 K45-60 020807 Haukeland Urine E.coli 
 76 K45-69 200807 Haukeland Urine E. coli 
 77 K46-10 100907 Haukeland Urine E. coli 
 78 K46-21 140907 Haukeland Urine E. coli 
 79 K46-32 200907 Haukeland Urine E. coli 
 80 K46-48 041007 Haukeland Operation wound E. coli Same patient as K46-58 




82 K46-58 151007 Haukeland Drain E. coli Same patient as K46-48 
83 K46-64 191007 Haukeland Urine E. coli 
 84 K47-20 161107 Haukeland Urine E.coli 
 85 K47-21 161107 Haukeland Urine E. coli 
 86 K47-24 231107 Haukeland Urine E. coli 
 87 K47-31 301107 Haukeland Urine E. coli 
 88 K47-33 301107 Haukeland Urine E. coli 
 89 K36-55 050107 Sykehuset i Vestfold Abdominal abscess E.coli 
 90 K36-72 170107 Sykehuset Østfold Urine E.coli 
 91 K36-76 190107 Sørlandet Sykehus Urine E.coli 
 92 K41-06 310107 Rikshospitalet Urine E.coli 
 93 K41-19 230207 UNN Urine E.coli 
 94 K41-32 160307 Haugesund Urine E.coli 
 95 K41-55 030407 Sykehuset i Vestfold Urine E.coli 
 96 K44-05 020507 Ullevål Urine E.coli 
 97 K44-22 110507 UNN Urine E.coli 
 98 K44-32 230507 Sykehuset Østfold Urine E.coli 
 99 K45-58 010807 Sørlandet Sykehus Urine E.coli 
 100 K45-66 130807 Sykehuset Østfold Urine E.coli 
 101 K46-19 130907 St.Olavs Hospital Blood culture E.coli 
 102 K46-20 130907 Sykehuset i Vestfold Urine E.coli 
 103 K46-28 190907 Sørlandet Sykehus Urine E.coli 
 104 K46-34 250907 Haugesund Urine E.coli 
 105 K46-35 250907 Haugesund Urine E.coli 
 106 K46-46 041007 Helse Nord-Trøndelag Blood culture E.coli 
 107 K46-66 241007 St.Olavs Hospital Blood culture E.coli 
 108 K46-81 291007 UNN Urine E.coli 
 
  2008           
Number  K-res number Received Hospital Material Specie Comments 
109 K47-78 241207 Haukeland Urine E. coli 
 110 K47-79 241207 Haukeland Urine E. coli 
 111 K48-3 020108 Haukeland Urine E. coli 
 112 K48-9 080108 Haukeland Urine E. coli 
 113 K48-12 110108 Haukeland Urine E. coli 
 114 K48-17 300108 Haukeland Urine E. coli 
 115 K48-26 130208 Haukeland Urine E. coli 
 116 K48-48 060308 Haukeland Urine E. coli Same patient as K54-52 
117 K49-14 070508 Haukeland Urine E. coli Same patient as K53-65 
118 K49-31 280508 Haukeland Urine E. coli 
 119 K49-40 050608 Haukeland Urine E. coli 
 120 K49-63 020708 Haukeland Urine E. coli 
 121 K49-66 070708 Haukeland Urine E. coli 
 122 K49-70 150708 Haukeland Urine E. coli 
 123 K52-12 110808 Haukeland Urine E. coli 
 124 K52-40 40908 Haukeland Urine E. coli 




126 K52-78 101108 Haukeland Urine E. coli Same patient as K53-43 
127 K53-43 111108 Haukeland Urine E. coli Same patient as K52-78 
128 K53-47 101208 Haukeland Blood culture E. coli 
 129 K53-58 11208 Haukeland Urine E. coli 
 130 K53-65 120808 Haukeland Urine E. coli Same patient as K49-14 
131 K48-1 030108 Sykehuset i Vestfold Abdominal abscess E.coli 
 132 K48-2 020108 Sykehuset Østfold Urine E.coli 
 133 K48-38 200208 Sykehuset Østfold Urine E.coli 
 134 K48-57 270308 Sørlandet Sykehus Urine E.coli 
 135 K49-5 050508 Sørlandet Sykehus Urine E.coli 
 136 K49-25 270508 Sykehuset i Vestfold Urine E.coli 
 137 K49-29 230508 Sykehuset Østfold Urine E.coli 
 138 K49-34 300508 Molde Sjukehus Urine E.coli 
 139 K49-75 160708 Sørlandet Sykehus -  E.coli 
 140 K49-78 230708 Helse Nord-Trøndelag Secretion from gallbladder E.coli 
 141 K52-3 290708 Stavanger Universistetssykehus Urine E.coli 
 142 K52-4 240708 Sykehuset i Vestfold Urine E.coli 
 143 K52-15 120808 Sykehuset i Vestfold Urine E.coli 
 144 K52-24 190808 Sykehuset Innlandet Abdominal pus E.coli 
 145 K52-28 210808 Sørlandet Sykehus Urine E.coli 
 146 K52-44 110908 Stavanger Universistetssykehus Pelvic abscess E.coli 
 147 K52-48 160908 Haugesund Urine E.coli 
 148 K52-62 021008 Sykehuset Østfold Urine E.coli 
 149 K53-45 131108 Sørlandet Sykehus Urine E.coli 
 150 K53-68 121208 Helse Nord-Trøndelag Urine E.coli 
 
  2009           
Number  K-res number Received Hospital Material Specie Comments 
151 K54-02 210109 Haukeland Urine E. coli 
 152 K54-42 060209 Haukeland Urine E. coli Same patient as K48-48 
153 K54-60 090209 Haukeland Urine E. coli 
 154 K55-66 040309 Haukeland Urine E. coli 
 155 K57-52 150409 Haukeland Urine E. coli 
 156 K57-76 120509 Haukeland Urine E. coli 
 157 K58-06 120609 Haukeland Urine E. coli Same patient as K49-70 
158 K58-11 220609 Haukeland Urine E. coli 
 159 K58-12 260609 Haukeland Urine E. coli 
 160 K58-13 290609 Haukeland Urine E. coli 
 161 K61-02 040809 Haukeland Urine E. coli 
 162 K61-12 010909 Haukeland Urine E. coli 
 163 K61-13 020909 Haukeland Urine E. coli 
 164 K61-17 150909 Haukeland Urine E. coli 
 165 K61-40 051009 Haukeland Urine E. coli 
 166 K58-05 040609 Sørlandet Sykehus Urine E.coli 
 167 K58-08 180609 Ullevål Urine E.coli 
 168 K58-24 230709 Stavanger Universitetssykehus Urine E.coli 




170 K53-75 050109 UNN Urine E.coli 
 171 K53-80 160109 Sørlandet Sykehus Urine E.coli 
 172 K55-04 160209 Sørlandet Sykehus Urine E.coli 
 173 K55-55 260209 Sørlandet Sykehus Urine E.coli 
 174 K57-43 060409 Sørlandet Sykehus Urine E.coli 
 175 K57-44 070409 Sørlandet Sykehus Urine E.coli 
 176 K57-53 150409 Sørlandet Sykehus Urine E.coli 
 177 K58-23 200709 Sørlandet Sykehus Urine E.coli 
 178 K61-43 061009 Haugesund Sjukehus Urine E.coli 
 179 K61-76 061109 Ullevål Urine E.coli 
 180 K61-78 171109 Molde Sjukehus Urine E.coli 
 181 K61-81 241109 Stavanger Universitetssykehus Urine E.coli 
 182 K71-39 301109 Ullevål Tracheal secretion E.coli 
 183 K71-40 011209 Ullevål Urine E.coli 
 184 K71-58 071209 Ullevål Urine E.coli 
 185 K71-61 101209 Sykehuset Vestfold Urine E.coli 
 
  2010           
Number  K-res number Received Hospital Material Specie Comments 
186 K63-77 290310 Haukeland Urine E.coli 
 187 K66-56 260410 Haukeland Urine E.coli 
 188 K67-10 280610 Haukeland Urine E.coli 
 189 K68-16 151210 Haukeland Urine E.coli 
 190 K68-26 131010 Haukeland Urine E.coli 
 191 K68-76 081210 Haukeland Blood culture E.coli 
 192 K63-47 120210 Sykehuset Østfold HF Urine E.coli 
 193 K63-70 120310 Sykehuset Østfold HF Blood culture E.coli 
 194 K63-73 160310 Ullevål Urine E.coli 
 195 K63-75 180310 Ullevål Urine E.coli 
 196 K66-47 140410 St.Olavs Hospital Urine E.coli 
 197 K66-50 190410 Rikshospitalet Urine E.coli 
 198 K67-03 070610 Sykehuset i Vestfold Urine E.coli 
 199 K67-18 020710 Sykehuset Vestfold Urine E.coli 
 200 K67-29 120710 Sørlandet Sykehus Blood culture E.coli 
 201 K67-45 020810 Sykehuset i Vestfold Urine E.coli 
 202 K67-51 090810 Sørlandet Sykehus Urine E.coli 
 203 K67-58 160810 Sykehuset Østfold HF Abdominal pus E.coli 
 204 K68-07 210910 Sykehuset Innlandet HF Urine E.coli 
 205 K68-14 011010 Stavanger Universitetssykehus Urine E.coli 
 206 K68-15 011010 Sørlandet Sykehus Urine E.coli 
 207 K68-29 191010 Molde Sjukehus Wound secretion E.coli 
 208 K68-54 061110 Helse Nord-Trøndelag Vaginal abscess E.coli 
 209 K68-57 171110 Stavanger Universitetssykehus Urine E.coli 
 210 K68-68 241110 Nordlandssykehuset Blood culture E.coli 




Table 2. Collection 3 (n=12).  
Collection 3 
    Number K-res Number Received  Hospital Material Specie 
1 K29-48 291205 Haukeland Urine E.coli 
2 K30-44 150306 Haukeland Urine E.coli 
3 K47-31 301107 Haukeland Urine E. coli 
4 K48-26 130208 Haukeland Urine E. coli 
5 K53-47 101208 Haukeland Blood culture E. coli 
6 K52-15 120808 Vestfold Urine E.coli 
7 K57-52 150409 Haukeland Urine E. coli 
8 K58-13 290609 Haukeland Urine E. coli 
9 K61-43 61009 Haugesund  Urine E.coli 
10 K71-61 101209 Vestfold Urine E.coli 
11 K63-77 290310 Haukeland Urine E.coli 
12 K68-26 131010 Haukeland Urine E.coli 
 
Table 3. 32 AmpC with insert -positive isolates (IS911 and IS10) included in the PFGE; 
Haukeland (n=29), Vestfold (n=2), and Haugesund (n=1).  
PFGE isolates         
Number K-res Number Received  Hospital Material Specie 
1 K29-48 291205 Haukeland Urine E.coli 
2 K29-77 310106 Haukeland Blood culture E.coli 
3 K29-80 030206 Haukeland Urine E.coli 
4 K30-24 270206 Haukeland Urine E.coli 
5 K30-36 030306 Haukeland Urine E.coli 
6 K30-44 150306 Haukeland Urine E.coli 
7 K34-8 230806 Haukeland Urine E.coli 
8 K36-3 061106 Haukeland Urine E.coli 
9 K41-39 220307 Haukeland Urine E. coli 
10 K46-64 191007 Haukeland Urine E. coli 
11 K47-31 301107 Haukeland Urine E. coli 
12 K48-9 080108 Haukeland Urine E. coli 
13 K48-17 300108 Haukeland Urine E. coli 
14 K48-26 130208 Haukeland Urine E. coli 
15 K49-14 070508 Haukeland Urine E. coli 
16 K49-40 050608 Haukeland Urine E. coli 
17 K52-12 110808 Haukeland Urine E. coli 
18 K52-15 120808 Vestfold Urine E.coli 
19 K52-78 101108 Haukeland Urine E. coli 
20 K53-47 101208 Haukeland Blood culture E. coli 
21 K54-02 210109 Haukeland Urine E. coli 
22 K57-52 150409 Haukeland Urine E. coli 
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23 K57-76 120509 Haukeland Urine E. coli 
24 K58-13 290609 Haukeland Urine E. coli 
25 K61-12 010909 Haukeland Urine E. coli 
26 K61-40 051009 Haukeland Urine E. coli 
27 K61-43 61009 Haugesund  Urine E.coli 
28 K71-61 101209 Vestfold Urine E.coli 
29 K63-77 290310 Haukeland Urine E.coli 
30 K67-10 280610 Haukeland Urine E.coli 
31 K68-16 151210 Haukeland Urine E.coli 





















Table 1. General prescription for mastermix for PCR-based methods.  
General Mastermix  Amount 
JumpStart REDTaq  ReadyMix PCR Reaction Mix 
(Sigma-Aldrich)  
500µl 
Primer F (50pmole/µl) 8µl 
Primer R (50pmole/µl) 8µl 
ddH2O 384µl 
Total 900µl  
 
Table 2. General prescription for sequencing mastermix. 
Sequencing Mastermix (pr.reaction) Amount 
Big Dye v 3.1 (Applied Biosystems) 1µl 
5x Sequencing buffer (Applied Biosystems) 3µl 
Primer 3.2 pmole/µl (Eurogentec S.A)  0.5µl 
ddH2O 15µl 
DNA template 0.5µl 
Total 20µl 
 
Table 3. PCR program parameters used in this study. 
PCR Initial 
denaturation 








95°C/5min 30 95°C/30sec 55°C/30sec 72°C/2min 72°C/5min 
(then 4°C→∞) 
IS911 95°C/5min 30 95°C/30sec 55°C/30sec 72°C/1min 72°C/7min 
(then 4°C→∞)  
blaTEM 94°C/1min 25 95°C/30sec 50°C/30sec 72°C/1min 72°C/7min 
(then 4°C→∞) 




94°C/5min 30 94°C/15sec 55°C/15sec 72°C/40sec 72°C/4min 
(then 4°C→∞) 




95°C/5min 30 95°C/30sec 67°C/30sec 72°C/1min 72°C/5min 
(then 4°C→∞) 
Sequencing  96°C/5min 25 96°C/10sec 50°C/10sec 60°C/4min 4°C→∞ 










Table 4. Primers used in this study. 
 
Name DNA sequence 5’-3’ Target site Amplicon size 
(bp)  
Reference  
16SrDNA-F AGAGTTTGATCMTGGCTCAG  
 
16SrDNA ~1500 bp Modified 
from fD1 and 
fD [38] 
16SrDNA-R ACGGHTACCTTGTTACGACTT  
 
Modified 
from rP1 and 
rP2, rP3 [38] 
AmpCF TTCCTGATGATCGTTCTGCC  
 
frdD - [57] 
AmpCintR GCAAGTCGCTTGAGGATTTC  
 
blaAmpC [33] 




aac(6´)-Ib-F TTGCGATGCTCTATGAGTGGCTA aac(6’)-Ib 482 bp [40] 
aac(6´)-Ib-R CTCGAATGCCTGGCGTGTTT 
gyrA6 CGACCTTGCGAGAGAAAT QRDR of 
gyrA 
620 bp [59] 
gyrA631R GTTCCATCAGCCCTTCAA 
parCF TGAATTTAGGGAAAACGCCTA QRDR of 
parC 
559 bp [60] 
parCR GCCACTTCACGCAGGTTATG 




347 bp [41] 
O25pabBspe.R GCGAAATTTTTCGCCGTACTGT 








49 bp [42] 
ST131AR ACCTGGCGAAATTTTTCG 
IS911 1F CGGGAAACTCAGGGCGCGTT IS911 - This study 
IS911 5F TACCAGATGGGGCGCTGGCT IS911 - 
IS911 2R CGCCGGCACCCATTCGTTCT IS911 - 
IS911 4R TAGCGTCGCCACCAAGCACG blaAmpC - 





adkR CCG TCA ACT TTC GCG TAT TT 
fumCF TCA CAG GTC GCC AGC GCT TC fumC 806 bp 
fumCR GTA CGC AGC GAA AAA GAT TC 
fumCR1 TCC CGG CAG ATA AGC TGT GG 
gyrBF TCG GCG ACA CGG ATG ACG GC gyrB 911 bp 
gyrBR ATC AGG CCT TCA CGC GCA TC 
icdF ATGGAAAGTAAAGTAGTTGTTC
CGGCACA 
icd 878 bp 
icdR GGA CGC AGC AGG ATC TGT T 
mdhF ATG AAA GTC GCA GTC CTC 
GGC GCT GCT GGC GG 
mdh 932 bp 
mdhR TTA ACG AAC TCC TGC CCC 
AGA GCG TAT CTT TCT T 
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purAF CGC GCT GAT GAA AGA GAT GA purA 816 bp 
purAR CAT ACG GTA AGC CAC GCA GA 
recAF CGC ATT CGC TTT ACC CTG 
ACC 
recA 780 bp 
recAR TCG TCG AAA TCT ACG GAC 
CGGA 
 
Table 5. Positive and negative PCR controls used in this study. 
PCR Positive control Negative control 
16S rDNA Enterococcus faecalis 
A2-32, (ATCC 29212) 
E.coli A-81  
(ATCC 25922) 
ddH2O 
AmpC IS911 E.coli K63-77 E.coli A-81 
(ATCC 25922) 




AAC(6´)-Ib-cr E.coli K64-02 
K64-11 
 
ST131 PCR K5-56 E.coli A-81 
(ATCC 25922) 
ST131 Real-time PCR K5-56 E.coli A-81 
(ATCC 25922) 
 
Table6. Bacterial growth media used in this study.  
Lactose agar plates  
Tryptose Blood Agar Base (Oxoid)  
Lactose (Oxoid) 
Bromtymolblue solution 0.2% (Merck) 
ddH2O 
Brain Heart Infusion (BHI) broth 
BHI broth base (Oxoid)  
ddH2O 
 
Lactose agar plates w/ 100mg/ml ampicillin 
Tryptose Blood Agar Base (Oxoid)  
Lactose (Oxoid)  
Bromtymolblue solution 0.2% (Merck) 
ddH2O 
Ampicillin (Bristol-Myers Squibb) 
Mueller-Hinton agar (MH)  
MH II agar base (Becton, Dickinson and 










Table 7. Reagents and solutions  
PIV-buffer 
1M NaCl (Merck) 
10mM Tris-HCl pH 7.6 (Sigma-Aldrich) 
 
TE-buffer 
10 mM Tris-HCl pH 8 (Sigma-Aldrich) 
0.1 mM EDTA (Sigma-Aldrich) 
ddH2O 
Lysis buffer (for 5 isolates) 
10ml basic buffer 
0.02g Sodium deoxycholate (Sigma-Aldrich) 
0.5g N-laurolsylsarcosine (Sigma-Aldrich) 
0.01g lysosyme (Sigma-Aldrich) 
1µl RNase One (10U/µl) (Promega) 
ESP-buffer 
0.5 M EDTA (pH 9.0-9.5) 
1% N-laurolsylsarcosine (Sigma-Aldrich) 
 
 
Restriction enzyme buffer with bovine serum 
albumin (BSA) 
Buffer 4 (10x) (New England BioLabs) 
BSA (100x) (New England BioLabs) 
ddH2O 
Xba I mixture 
Buffer 4 (10x) (New England BioLabs) 
BSA (100x) (New England BioLabs) 
Xba I (20U/µl) (New England BioLabs) 
ddH2O 
GelRed staining solution 
45µl 10000X GelRed 
15 ml 1M NaCl2 
135 ml ddH2O 
10X TBE buffer 
108 g Tris Base (Sigma-Aldrich) 
55 g Boric acid (Sigma-Aldrich) 
40 ml 0.5M EDTA pH 8.0 (Sigma-Aldrich) 
ddH2O to 1 litre 
Basic buffer 
0,5 % Brij 58 (Merck) 
1 M Tris-HCl pH 8 (Sigma-Aldrich) 




8.5 g NaCl (Merck) 
ddH2O to 1 litre  
Thiurea Stock 5mM 
0,389 g 
1 litre ddH20 
 
Table 8. Mastermix used for PCR-based detection of ST131 
Mastermix  Amount 
JumpStart REDTaq ReadyMix PCR 
Reaction Mix (Sigma-Aldrich)  
250µl 
O25pabBspe.F (50pmole/µl) 8µl 
O25pabBspe.R (50pmole/µl) 8µl 
trpA.F (50pmole/µl) 4.8µl 
trpA2.R (50pmole/µl) 4.8µl 
ddH2O 174.4µl 







Table 9. Mastermixes used for real-time PCR detection of ST131 
Mastermix “T” assay  Amount 
SYBR Green  250µl 
ST131 TF (50pmole/µl) 8µl 
ST131 TR (50pmole/µl) 8µl 
ddH2O 195µl 
Total 450µl  
 
Mastermix “A” assay  Amount 
SYBR Green  250µl 
ST131 AF (50pmole/µl) 8µl 
ST131 AR (50pmole/µl) 8µl 
ddH2O 195µl 
Total 450µl  
 
Table 10. PCR programs used for real-time PCR detection of ST131 
Cycle Program 1 Program 2 
Hold 1 95°C/5min 95°C/15min 
Cycling (40 repeats)  95°C/5sec 94°C/20sec 
 58°C/30sec 65°C/20sec 
  72°C/20sec 
Hold 2  65°C/30sec 
Melt curve analysis  95°C/15sec 95°C/30sec 
 60°C/1min 60°C/1min 






















Figure 1. Band sizes of the 1 Kb Plus 




Figure 2. Low range PFG marker, 




















Figure 1. ClustalW alignment of the nucleotide sequence of the AmpC IS911 region in 
colletion 3 isolates from Haukeland University Hospital, aligned against IS911 AY555729.1 





Figure 2. ClustalW alignment of the QRDR of gyrA from collection 3 (divided into hospital of 
origin). Reference sequence used was GyrA NP_416743. 
 
 
Figure 3. ClustalW alignment of the QRDR of parC from collection 3 (divided into hospital 
of origin). Reference sequence used was ParC NP_417491. 
